principles of scientific writing for an international audience

Successful(Scien+fic(Wri+ng(Eugene(Elbert,(MS((Johns(Hopkins((

University,(U.S.)(Special(thanks(to(:(Paul(Siegel(MD,(MPH(

9F10(August(2012(

Biological(Threat(Reduc+on(Program((of(the(

Defense(Threat(Reduc+on(Agency((DTRA)(

Biological(Threat(Reduc+on(Program((

•  Consolidate(especially(dangerous(pathogens((EDPs)(into(one(or(two(safe,(secure(central(reference(laboratories(or(repositories(

•  Build(and(sustain(longFterm(partnerships(through(interna+onal(scien+fic(engagement(and(coopera+on(

•  Improve(capacity(to(detect,(diagnose(and(report(outbreaks(and(poten+al(pandemics(by(providing(training(to(personnel(of(the(appropriate(facili+es(

Biological(Threat(Reduc+on(Program((BTRP)(

•  EDPs(for(human(and(animal(health(include:(o  Avian(and(pandemic(influenza((influenza(viruses)(o  CrimeanFCongo(Hemorrhagic(Fever((CCHF(virus)(o  Anthrax((Bacillus(anthracis)(o  Brucella((Brucella(species)(o  Tularemia((Francisella(tularensis)(o  Botulism((Clostridium(botulinum)(o  Tick(Borne(Encephali+s((TBE(virus)(o  Plague((Yersinia(pes6s)(o  Foot(and(Mouth(Disease((FMD)(o  Glanders(o  Newcastle(Disease(Virus(o  Rinderpest(o  Pox(viruses((goat(and(sheep(pox)(o  Swine(fevers((African(and(Classical(Swine(Fever)(

•  Although( the( BTRPFprovided( training( focus( on( these( pathogens,(the(knowledge(and(skills(learned(and(prac+ced(are(applicable(to(a(broad( range( of( other( infec+ous( diseases( and( public( and( animal(health(concerns(

BTRPFProvided(Training(

Courses(include:((•  Disease(recogni+on;((•  Laboratory(equipment(use(and(maintenance;((•  Biosafety(and(security;((•  Laboratory(safety;((•  Laboratory(quality(systems;((•  Respiratory(protec+on(program;((•  Purchasing(and(inventory(control;((•  Introduc+on(to(microbiology;((•  Introduc+on(to(molecular(biology;((•  Introduc+on(to(immunology/serology;((•  Diagnos+c(assays(for(specific(EDPs;((•  Laboratory(management;((•  Sample(collec+on(and(processing;((•  Basics(of(epidemiology;(and(others(

BTRP(Summary(

•  Enhancement(of(exis+ng(surveillance(capacity(through(expansion(of(generic(skills(

•  Development(of(capacity(for(rapid(detec+on((PCR(and(ELISA),(which(contributes(to(public(health(

•  Improved(biosafety(and(biosecurity(for(laboratory(personnel(

•  BTRPFprovided(training(complements(the(Ministry(training(requirements(for(specialists(

Successful(Scien+fic(Wri+ng(

Introduc+on(

Objec+ves(of(the(workshop:((•  To((introduce(basic(concepts(of(scien+fic(approach(•  To(detail(the(structure(and(format(of(scien+fic(papers.(•  To(compare(examples(of(different(research(designs.(•  To(examine(components(of(a(scien+fic(paper.(•  To(cri+cally(examine(published(examples(of(scien+fic(wri+ng.(

•  To(apply(new(wri+ng(skills(to(draging(an(abstract.(•  To(learn(about(the(submission(process(for(publica+ons,(funding(proposals,(and(presenta+ons(

Why(do(we(publish?(

•  Presen+ng(research(•  Reaching(global(scien+fic(community(

•  Advancing(science(•  Educa+on(•  Funding(and(credibility((

Repor+ng(Scien+fic(Research(

•  Hypothesis(or(research(ques+on(•  Planned(research(•  Ethics((

– Plagiarism(– Misuse(of(data(and(informa+on(– Conflict(of(interest(–  Integrity(– Human(subject(research(

Process(of(scien6fic(wri6ng(

Hypothesis(

Study(plan(

Experiment(

Data(processing(Results(genera+on(

Having((

journal,(

audience((

in(mind(

Wri+ng((ar+cle(

Submiing(

General(Guidelines(for(Scien+fic(Papers:(Style(and(Content(

EASE(guidelines(

•  Complete,(concise(and(clear(

•  For(effec+veness(of(interna+onal(coopera+on(all(publica+ons(should(be:(

•  COMPLETE,(CONCISE(AND(CLEAR!(

•  IMPORTANT((

•  Do(not(include(irrelevant(informa+on(•  Informa+on(should(not(be(repeated(•  Include(only(necessary(tables(and(figures(•  Cap+ons(–(informa+ve(but(concise(•  Delete(redundancies(•  Define(abbrevia+on(at(first(use(•  Do(not(overFgeneralize(•  Numbers(for(all(numerals(

General(Guidelines(for(Scien+fic(Papers:(Style(and(Content(

Content(

•  Study(should(be(planned(in(advance(•  The(journal(and(the(audience(should(be(chosen(

•  Informa+on(should(be(organized(•  All(the(components(of(scien+fic(ar+cle(should(be(present(and(sa+sfy(the(guidelines(for(a(chosen(journal(

Repor+ng(Guidelines:(Content(

•  Dis+nguish(your(original(ideas(•  Paraphrase(text(from(other(sources(•  Proper(terms((plant(community(vs.(phytocoenosis)(•  Define(every(uncommon(term((•  Avoid(ambiguity(•  Be(clear(what(you(regard(as(100%(when(repor+ng(%(•  SI(units((interna+onal(system(of(units;(metric)(•  Decimal(point((•  Remember(that(the(text(will(be(read(by(foreigners(

•  Make(posi+ve,(objec+ve(asser+ons,(directly(supported(by(the(results,((with(necessary(qualifica+ons(and(caveats(

•  Don’t(oversell:((“This(result(clearly(proves(that(the(neural(network(approach(is(superior(and(will(revolu+onize(research(methods”.(

•  Don’t(base(substan+al(claims(on(unpublished(data(or(on(“experience”(without(objec+ve(suppor+ng(evidence.(((

(•  If(you(rely(on(a(reference(to(draw(a(conclusion,(be(sure(the(reference(supports(the(idea,(and(say(where(the(support(may(be(found(in(the(reference.(

Repor+ng(Guidelines:(Content(

A(Dic+onary(of(Useful(Research(Phrases(((•  "It(has(long(been(known..."(

•  "It(is(believed(that..."(•  "It(is(generally(believed(

that..."(

•  "A(sta+s+cally(oriented(projec+on..."(

•  “Typical(results(are(shown”(•  “Obviously,(we(will(need(

addi+onal(studies”(•  “Authors(thanks(Joe(in(

conduc+ng(experiment(and(George(for(helpful(comments”(

•  I(didn't(look(up(the(original(references(

•  I(think(•  My(friends(think(so,(too(

•  Wild(guess(

•  Best(results(are(shown(•  I(don’t(understand(anything((

•  Joe(did(the(work(and(George(explained(it(to(me(

Example(

“In(order( to(provide(analy+c(control(during( forensicFchemical( inves+ga+on,( it( is( customary( to( use( highly(sensi+ve(and(specific(analysis(methods.(Very(popular(in( the( prac+ce( of( chemicFtoxic( studies( is( the( TLC(method(in(view(of(its(accessibility,(ease(of(conduc+ng(and(expressiveness.(Due(to(the(possibility(of(changing(not( only( sorbents( but( also( solvents,( it( is( possible( to(quickly(solve(the(problems(of(separa+on”(

Repor+ng(Guidelines:(Text(Structure(

•  Simple(sentences,(should(not(be(very(long(•  Avoid(passive(voice(•  Text(should(be(cohesive,(logically(organized(•  Each(paragraph(should(start(with(a(topic(sentence(•  Use(text(tables(•  Make(figures(and(tables(understandable(by(themselves(•  Explain(your(figures(and(charts,(and(jus+fy(their(inclusion.((Do(not(just(show(them(with(no(stated(reason.(

Text(tables(Original(sentence:(•  Iron(concentra+on(means((±standard(devia+on)(were(as(follows:(11.2±0.3(mg/dm3(in(sample(A,(12.3±0.2(mg/dm3(in(sample(B,(and(11.4±0.9(mg/dm3(in(sample(C.(

Modified:(•  Iron(concentra+on(means((±standard(devia+on,(in(mg/dm3)(were(as(follows:(•  sample(B((12.3±0.2(•  sample(C((11.4±0.9(•  sample(A((11.2±0.3(

Replace(phrases(with(a(single(word(

•  Considering(this(fact(•  In(the(rela+on(to((•  Exceeding(number(

•  In(the(previous(case(•  In(the(absence(•  In(large(number(of(cases(

Passive(Voice(

“Have(you(ever(been(told(to(use(passive(voice”(( ( ( (or(

“Did(anyone(tell(you(to(use(passive(voice”(Examples:*•  “James(Watson(was(awarded(the(Nobel(Prize(for(discovering(the(molecular(structure(of(DNA.“(vs.(

•  "The(Nobel(CommiSee(awarded(James(Watson(the(Nobel(Prize(for(discovering(the(molecular(structure(of(DNA."(

Passive(voice(

Nobody(takes(responsibility(in(passive(voice:(

“Mistakes(were(made(during(the(experiment”(

vs.(We(made(mistakes(during(the(experiment(

“It(is(shown(in(the(table”(vs.*The(table(shows((

Example(

Common(dysfunc+on(of(the(immune(system(was$shown$in(the(trials(on(humans(and(animals(__________________________________(

Trials(on(humans(and(animals(show(a(common(dysfunc+on(of(the(immune(system(

Correct(Use(of(Passive(Voice(

•  When(the(ac+on(is(more(important(than(the(agent(of(it((as(in(Materials(and(Methods)(

•  In(order(to(emphasize(somebody(other(than(the(ac+ng((agent(

•  When(the(agent(is(unknown(

Repor+ng(Guidelines:(Language(

•  Use(commonly(known(words,(but(not(idioma+c(expressions(

•  Define(abbrevia+ons((avoid(them(in(abstract)(

•  Spelling((•  Past(tense(in(body,(present(in(general(statements(

•  Refer(to(the(author(as(“we”(or(“I”(not(“the(author”(

Repor+ng(Guidelines:(Language(

Transforma2on*of*verbs*into*nouns*(

Obtained(es+mates(–(es+mated(

Gained(improvementF(improved(

Showed(growth(–(grew(

Made(a(decision(–(decided(

Common(Fallacies(in(Wri+ng ((

•  Non$Causa$Pro$Causa*Fallacies*—*No*Cause*for*Cause*

•  Asempts(to(establish(a(causal(rela+onship(–  Cum(Hoc,(Ergo(Propter(Hoc((

–  Post(Hoc,(Ergo(Propter(Hoc((–  The(Regression(Fallacy((–  Texas(Sharpshooter(Fallacy(

Fallacies(in(Wri+ng($Cum$Hoc,$Ergo$Propter$Hoc*—*With*This,*Therefore*

•  African(American(popula+on(is(more(likely(to(experience(metabolic(consequences(of(Chronic(Kidney(Disease((CKD)(before(reaching(the(eGFR(<60(ml/min(threshold(…(that(these(observa+ons(support(a(need(to(adapt(clinical(prac+ce(guidelines(shiging(screening(for(CKD(to(a(higher(eGFR(threshold(specifically(for(African(Americans((1)(

(•  The(assump6on(that(the(measured(clinical(parameters(in(this(

representa6ve(popula6on(are(physiologically(linked(to(CKD(in(African(Americans(is(simplis6c(and(ignores(the(effects(of(a(combina6on(of(gene6c(and(physiologic(adapta6ons(superimposed(on(a(background(of(social(and(environmental(factors(that(account(for(minority(health(dispari6es((2)(

(•  Lesson:*Adjustment(for(possible(confounders(and(other(sources(of(

bias(*

Fallacies(in(Wri+ng($Post$Hoc,$Ergo$Propter$Hoc*—*AAer*This,**Therefore* *Because*of*This**

•  “Since(that(event(followed(this(one,(this(event(must(have(caused(that(one.”(It(also(is(referred(to(as(“false(cause”(or(“coincidental(correla+on.”(

•  7(women(in(California(developed(ovarian(cysts(taking(the(new(mul+phasic(oral(contracep+ve(pills(which(led(to(case(series(report(and(media(prin+ng(the(story([1].((

•  No(associa6on(was(shown(in(followYup(studies([2]((•  Lesson:*Checking(for(possible(confounders,(conduc+ng(valida+on(studies(before(jumping(to(conclusions,(repor+ng(on(it(in(wri+ng(

Fallacies(in(Wri+ng(*Texas*Sharpshooter*Fallacy**

•  In(medical(research,(this(fallacy(occurs(when(inves6gators(select(certain(data(to(demonstrate(a(causeYeffect(rela6onships.(

Outbreak(foci?(

Fallacies(in(Wri+ng(*The*Art*of*Argumenta$

– Argumentum$ad$Ignoratum*(Appeal*to*Ignorance):(Absence(of(evidence(is(not(evidence(of(absence(

* Width*of*Confidence*Interval(±w)* Sample*Size(n)*

0.01( 9612(

0.02( 2403(

0.03( 1068(

0.05( 384(

0.10( 96(

0.15( 43(Sample*sizes*required*to*es2mate*a*true*prevalence*of*0.50*with*95%*confidence*intervals*of*different*widths*(±w)*

(Lesson:*Making(sure(that(the(sample(size(is(large(enough.(Recognizing(beneficence(and(nonFmaleficence(

Fallacies(in(Wri+ng(

$Argumentum$ad$Verecundiam*(Appeal*to*Authority):*Users(of(this(fallacy(ogen(call(upon(the(published(works(of(others(to(bolster(their(arguments,(without(ques+oning(the(accuracy,(reliability,(or(validity(of(those(sources(•  Quote(from(an(editor(as(a(condi+on(for(publica+on(highlights(

the(problem:(“you(cite(Leukemia([once(in(42(references].(Consequently,(we(kindly(ask(you(to(add(references(of(ar6cles(published(in(Leukemia(to(your(present(ar6cle”((1)(

•  Editors'(incen+ve(to(inflate(impact(factors(through(selfFcita+on(

•  Survey(found(that(having(a(tenure(posi6on(also(increased(coercion(

•  Lesson:((Being(true(to(your(work(

Fallacies(in(Wri+ng($Argumentum$ad$An;quitatem*(Appeal*to**Tradi2on*or*History)((

“(Talking(about(acupuncture)(I(think(it(is(insul+ng(to(say(that(Chinese(people(would(carry(on(with(some(sort(of(mys+cal(belief(when(it(didn’t(work”(

“Well,(you(know(–(acupuncture(is(one(of(those(amazing(things.(I(mean(it(has(been(around((for(several(thousand(years(.(.(.(there(is(a(huge(amount(of(validity(to(what(it(represents,((and(there(has(to(be(–(or(it(wouldn’t(have(survived(such(a(long(+me(“((Lesson:((Not(making(unsupported(claims(

7/28/2012(

•  Argumentum$ad$Populum*(Appeal*to*the*People*or*Popularity)((

•  4(from(5(den+sts(recommend(sugarFfree(“Trident”“(chewingFgum!(

•  The(adver+sement(“forgot”(to(men+on(“If(pa+ents(INSIST(to(use(chewingFgum”.(They(also(hid(each(5th(den+st(recommended(to(avoid(the(use(of(chewingFgum.(

•  «Thus(based(on(the(assessment(of(leading(Russian(clinics(“Sangviri+n”(is(one(of(the(effec+ve(modern(an+microbial(drug(of(local(and(commonF(resorp+ve(ac+on(for(preven+on(and(treatment(of(different(infec+ous(diseases([14–17].»(

Fallacies(in(wri+ng ((

Fallacies(in(Wri+ng(Myths*of*Beneficence**An(analysis(of(60(adver+sements(that(had(appeared(in(the(Bri+sh(Medical(Journal(between(1999(and(2001(demonstrated(that(drug(adver+sing(uses(strong(imagery(to(fabricate(mythical(associa+ons(between(medical(condi+ons(and(branded(drugs,(and(that(drug(adver+sing(manipulates(readers’(percep+ons(by(subtle(appeal(to(ancient(and(modern(mythological(founda+ons(of(humanism(and(Western(psychology.(( 39(

False*Dichotomy((This(is(also(called(a(false(dilemma,(an(eitherYor(fallacy,(fallacy(of(false(choice,(or(blackYandYwhite(thinking.((

Most(wideFspread(false(dichotomy(in(scien+fic(repor+ng:(((Sta+s+cal(significance(

P(=(0.049(vs.(P(=(0.051(

Fallacies(in(Wri+ng(Essen2alism((Some(argument(in(print(or(spoken(word,(some(“essen+al(feature”(is(proposed(as(a(defining(characteris+c(of(an(otherwise(complex(issue(or(larger(problem(

(Each(scien+fic(specialty(looks(at(disease(differently.(For(example,(cancer(from(the(perspec+ve(of(a(general(surgeon,(a(pathologist(or(an(acupuncturist(are(completely(different.(((Lesson:(To(be(aware(of(specialized(terminology(and(body(of(knowledge(when(repor+ng(

Редукционизм$Efforts(to(simplify(the(problem(to(the(simple(rela+ons(((O’Connor(et(al.(2011):(“Reduc+onist(methods(of(disease(control(involve(the(removal(of(infec+on(or(the(infec+ous(agent,(implemen+ng(barriers(to(direct(and(indirect(transmission(or(by(increasing(inherent(or(acquired(immunity(to(the(infec+ous(agent.(However,(for(those(diseases(which(evade(such(methods(of(conven+onal(control,(a(more(comprehensive(understanding(of(the(complex(interac+ons(amongst(biological((agent(and(host(s)),(environmental,(economic(and(social(factors(which(can(affect(the(emergence(and(spread(of(an(infec+ous(disease(is(required.”(

Things(to(avoid:(•  Plagiarism((•  Fishing(expedi+ons(–(research(must(be(hypothesis(driven(•  Do(not(plan(your(study(in(order(to(use(your(results(to(pool(

evidence(against(the(same(problem((e.g.(metaFanalyses.((•  Do(not(fail(to(take(into(account(heterogeneity,(uncertainty(

and(dependence(•  Do(not(fail(to(have(a(robust(exploratory(data(analysis((EDA)(

before(proceeding(into(any(confirmatory(tes+ng((John(Tukey(teachings)(

•  Do(not(discount(the(importance(of(internal(and(external(validity(when(interpre+ng(results(

•  Do(not(underes+mate(the(sta+s+cs.((The(absence(of(evidence(is(not(the(evidence(of(absence(–(your(study(may(not(have(enough(power(to(detect(anything(unless(you(have(large(numbers(

Things(that(annoy(reviewers(

–  Poor(English(–  Repe++on(–  Lack(of(structure(in(the(text(–  Sentences(that(are(too(convoluted(and(long((–  Lack(of(asen+on(to(detail((a(premature(drag(with(typographical(errors,(etc.)(

– Not(well(thought(out(statements((make(each(word(count)(

– Obscure(methods(or(not(well(described(– Oversta+ng(the(results(–  Too(long(of(a(paper(

Repor+ng(Guidelines:(Structure(•  IMRaD(standard((Introduc+on,(Methods,(Results,(and(

Discussion)(•  Design(Specific(–(EQUATOR(network(•  Journal(Fspecific(•  General:(

–  Title(Page(–  Conflict(of(Interest(No+fica+on(Page(–  Abstract(–  Introduc+on(– Methods(–  Results((–  Discussion(–  References(

Standardizing(Health(Repor+ng(

EQUATOR((Enhancing(Quality(and(Transparency(of(Health(Research)(network:(

“Too(oaen,(good(research(evidence(is(undermined(by(poor(quality(repor6ng”(

•  Raising(awareness(of(the(crucial(importance(of(good(repor+ng(of(research((

•  Becoming(the(recognized(global(center(providing(resources,(educa+on(and(training(rela+ng(to(the(repor+ng(of(health(research(and(use(of(repor+ng(guidelines(

•  Assis+ng(in(the(development,(dissemina+on(and(implementa+on(of(repor+ng(guidelines(

•  Monitoring(the(status(of(the(quality(of(repor+ng(across(health(research(literature(

•  Conduc+ng(research(rela+ng(to(the(quality(of(repor+ng(((

Guidelines(for(Repor+ng(Common(Study(Types(

•  CONSORT(–(Consolidate(Standards(of(Repor+ng(Trials(

•  STROBE(–(Strengthening(the(Repor+ng(of(Observa+onal(studies(

•  STARD(–(Standards(for(repor+ng(of(Diagnos+c(Accuracy(

•  QUOROM(–(Quality(of(Repor+ng(of(MetaFanalyses((under(CONSORT)(

Example(–(STROBE(checklist ((Item No Recommendation

Title and abstract 1 (a) Indicate the study’s design with a commonly used term in the title or the abstract (b) Provide in the abstract an informative and balanced summary of what was done and what was found

Introduction Background/rationale 2 Explain the scientific background and rationale for the

investigation being reported Objectives 3 State specific objectives, including any prespecified

hypotheses Methods Study design 4 Present key elements of study design early in the paper Setting 5 Describe the setting, locations, and relevant dates,

including periods of recruitment, exposure, follow-up, and data collection

Participants 6 (a) Cohort study—Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up Case-control study—Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls Cross-sectional study—Give the eligibility criteria, and the sources and methods of selection of participants (b) Cohort study—For matched studies, give matching criteria and number of exposed and unexposed Case-control study—For matched studies, give matching criteria and the number of controls per case

Study(Designs(in(Public(Health(

Experimental*(Interven2onal)*Studies* Observa2onal*Studies*

Randomized(Trials( Case(reports(

Community(Trials( Case(Series(

Therapeu+c/Preven+ve(Trials( CrossFsec+onal(Studies(

Surveillance((

Cohort(Studies((

CaseFControl(

Descrip+ve(

Analy+c(

Observa+onal(Descrip+ve(Studies(

•  Case(Reports(–(detailed(presenta+ons(of(a(single(case(or(a(handful(of(cases.((“Normal(Plasma(Cholesterol(in(an(88FYearFOld(Man(Who(Eats(25(Eggs(a(

Day(—(Mechanisms(of(Adapta+on”([Kern(J,(NEJM(1991;(324:896–899](

•  Case(Series(–survey(of(a(group(of(individuals(with(a(par+cular(disease(performed(at(a(single(point(of(+me.(“Pneumocy+s(pneumonia:(Los(Angeles”([MMWR(Morbidity(and(

Mortality(Weekly(Report(1981;30:250Y252](

CrossFSec+onal(Studies(

•  Describes(health(of(popula+ons((both(exposed(and(nonFexposed)(

•  Iden+fies(prevalent(cases(•  Finds(associa+on,(not(causa+on((•  BestFsuited(for(lisle(disability,(preFsymptoma+c(studies(

•  Surveys(•  Good(for(planning(health(care(

– Na+onal(Health(Surveys(are(a(good(example(

Surveillance(•  An(ongoing,(systema6c(collec6on,(analysis(and(interpreta6on(of(

healthYrelated(data(essen6al(to(the(planning,(implementa6on,(and(evalua6on(of(public(health(prac6ce(

•  Detec+on(and(no+fica+on(of(health(events(•  Collec+on(and(consolida+on(of(data(•  Inves+ga+on(of(cases(and(outbreaks(•  Rou+ne(Repor+ng((•  Feedback(

U.S.(CDC:(Ears,(EWIDS,(NTSIP,(ESP,(NEDSS,(FluNet,(BRFSS,(FoodNet,(etc.(Australia:((NNDSS(U.S.:(ProMED,(HealthMap(Canada:(FluWatch,(GPHIN(France:(GPs(Sen+nelles(Network(Asia:(APEC(EINet(WHO:(GOARN(Europe:(MedlSys(

CaseFControl(Studies(

•  Comparison(of(cases(versus(nonFcases((controls)(

•  Retrospec+ve(for(exposure(•  Matching(all(popula+on(characteris+cs(of(cases(to(those(of(controls((including(biases)(

•  Mostly(for(prevalent(cases((but(could(be(for(incident(cases,(too)(

Cohort(Studies(

•  To(support(the(rela+on(between(the(cause(and(disease(

•  Presence(or(absence(of(risk(factor(is(determined(before(outcome(occurs(

•  Longitudinal/prospec+ve/incidence(studies(•  Cohorts(are(free(of(disease(at(baseline(•  Cohorts(should(be(comparable(

•  Diagnos+cs(and(eligibility(should(be(defined(

Cohort(vs.(CaseFControl(

Popula+on(

Sample(of(diseaseFfree(individuals(

Exposed(

Not(Exposed(

Develop(Illness(

Don’t(Develop(Illness(

Exposed(

Not(Exposed(

Exposed(

Not(Exposed(

Not(Sick(

COHORT(STUDY(DATA(COLLECTION(

CaseFControl(Data(Collec+on( 55(

Experimental:(Control(Study(

(Controlled:(–  Inves+gator(decides(on(interven+on(

(Randomized:(– Gold(Standard(in(Epidemiological(research(

– Controls(for(confounding(– Prevents(selec+on(Bias(

Therapeu+c(vs.(Preven+ve:((

(((((Pa+ents(with(Disease(vs.(Popula+on(at(Risk(

Experimental:(Controlled(Studies(

Sample(of(diseaseFfree(individuals(

Exposed(

Not(Exposed(

Not(Sick(

(DATA(COLLECTION(

Exposure(occurs(naturally(

Inves+gator(Determines(Exposure(

COHORT((Observa+onal)(

CONTROLLED((Interven+onal)(

Randomized(Clinical(Trial(

Experimental(Popula+on(

Reference(Popula+on((

• (Sample(size(should(be(sufficient(• (Possibility(to(follow(up(during(the(trial(• (Par+cipants(should(be(informed(of(risks/(benefits/(blinding/(placebo(• (Inclusion(Criteria(

Experimental(Popula+on(

Reference(Popula+on((

Study(Popula+on(

Internal(Validity( External(Validity(58(

Randomized(Clinical(Trial(

•  Design(–  Simple(–  CrossFover,(factorial((

•  Sampling(•  Eligibility(criteria(•  Blinding:(single(vs.(double(•  Alloca+on:(Randomiza+on(•  FollowFup(•  Analysis(•  Therapeu+c(vs.(NonFtherapeu+c(

Randomized(Trial:(CONSORT(Flow(

Eligible((NonFeligible(Declined(

Alloca+on(using(randomiza+on(scheme(

FollowFup(

Included(in(analysis(

Protocol of clinical study (typical errors)

•  During(development(of(CS(protocol:(–  Fail(to(jus+fy(the(study(of(given(drug(by(the(given(indica+ons;(–  Absence(of(preFclinical(and(clinical((if(applicable)(trials;(–  The(objec+ves(of(study(are(not(listed((primary(and(secondary(

objec+ves),(hypothesis(of(study;(–  Mixed(concep+on(of(primary(objec+ve(of(study(and(criteria(of(

efficacy;(–  Sta+s+cs!(Instead(of(sample(size(jus+fica+on(and(sta+s+cal(power:(

“the(assessment(will(be(performed(with(PC,(Excel,(Student’s(methods,(etc.”;(

–  Vague(procedures(and(methods,(allowing(ambiguous(interpreta+on;(–  No(dates,(no(versions(

Protocol of clinical study (typical errors)

•  While(repor+ng(of(CS:((

–  Vague(descrip+on(of(study(popula+on,(that(unable(the(formula+on(of(conclusion(about(homoscendacity;(

(–  No(sta+s+cal(assessment(inclusion/exclusion(criteria(of(lost(followFup(

pa+ents;((–  No(side(therapy(details(and(its(effect(in(sta+s+cal(analysis;((–  No(severity(and(resolving(of(side(effects((e.g.(2(pa+ents(presented(the(

head(ache(–(no(terms,(methods(od(treatment,(outcome,(etc.);((–  No(pa+ents’(compliance(data;((–  Separate(reports(from(each(center(instead(of(allFcenters(consolidated(

report(…(

General(Guidelines(For(Selec+on(of(Study(Type(

Study*objec2ve( Study*type(

Study(of(rare(diseases( Case(control(studies(

Study(of(rare(exposure,(such(as(exposure(to(industrial(chemicals(

Cohort(studies(in(a(popula+on(group(in(which(there(has(been(exposure((e.g.(industrial(workers)(

Study(of(mul+ple(exposures,(such(as(the(combined(effect(of(oral(contracep+ves(and(smoking(on(myocardial(infarc+on(

Case(control(studies(

Study(of(mul+ple(end(points,(such(as(mortality(from(different(causes(

Cohort(studies(

Es+mate(of(the(incidence(rate(in(exposed(popula+ons(

Exclusively(cohort(studies(

Study(of(covariables(which(change(over(+me(

Preferably(cohort(studies(

Study(of(the(effect(of(interven+ons( Interven+on(studies(63(

Ecological*study*

CrossZsec2onal*study*

CaseZcontrol*study*

Cohort*study(and*RCT)*

Selec+on(bias(

N/A( 2( 3( 1(

Recall(bias( N/A( 3( 3( 1(

Loss(to(followFup(

N/A( N/A( 1( 3(

Confounding( 3( 2( 2( 1(

Time(Required(

1( 2( 2( 3(

Costs( 1( 2( 2( 3(

1Fslight;(2Fmoderate;(3Fhigh;(N/A=(not(applicable(

Costs(of(different(types(of(bias(for(different(study(designs(

Introduc+on(sec+on(

•  Iden+fy(a(gap(in(knowledge(or(knowFhow((study(problem)(o  Provide(key(background((scope/nature/magnitude(of(the(gap)(o  Be(clear(that(filling(this(gap(will(be(useful.(o  Describe(the(relevant(limita+ons(of(previous(studies(

•  Present(your(approach(to(filling(the(gap((study(purpose)(o  Be(clear(that(your(approach(is(new(o  Emphasize(that(your(approach(addresses(the(limita+ons(of(previous(studies(in(a(logical(and(compelling(way(

Purpose:(to(convince(the(reader(that(your(study(will(yield(knowledge(or(knowFhow(that(is(new(and(useful(

Oaen(requires(just(three(paragraphs(65(

Introduc+on(Checklist(Background Statement:

Scope nature magnitude of the gap Be clear that filling the gap is useful

Problem Statement Describe relevant limitations

Study Statement Be clear that your approach is new Emphasize that your approach addresses limitations

Summary Statement Summarizes the study

Introduc+on(sec+on((

•  No(major(difference(in(introduc+on(sec+on(between(study(types(

•  Some+mes(summary(statement(is(omised,(or(becomes(part(of(the(study(statement(

•  STROBE:(Introduc+on

Background/ra+onale 2 Explain(the(scien+fic(background(and(ra+onale(for(the(inves+ga+on(being(reported

Objec+ves 3 State(specific(objec+ves,(including(any(preFspecified(hypotheses

Introduc+on(sec+on(

The(next(four(slides(detail(the(introduc+on(checklist(process(for(four(separate(studies:(

•  Background(statement(

•  Problem(statement(

•  Study(statement(– General(descrip+on(of(the(surveillance(system(

•  Summary(statement(

Background*Statement:*

The(treatment(of(human(immunodeficiency(virus((HIV)(infec+on(has(undergone(considerable(change.(Protease(inhibitors(and(non–nucleosideFanalogue(reverseFtranscriptase(inhibitors,(when(used(as(part(of(combina+on(drug(regimens,(can(profoundly(suppress(viral(replica+on,(with(consequent(reple+on(of(CD4+(cell(counts.(

Mul+ple(clinical(trials(have(shown(the(virologic(and(immunologic(efficacy(of(the(newer,(highly(ac+ve(an+retroviralFdrug(combina+ons(by(measuring(the(plasma(load(of(HIV(RNA(and(CD4+(cell(counts.(In(addi+on,(prophylac+c(medica+ons(are(now(being(used(rou+nely(to(prevent(disseminated(Mycobacterium(avium(complex(infec+on

Problem*Statement*

Several(reports(have(described(reduc+ons(in(mortality(and(in(the(rate(of(hospitaliza+on(of(HIV(infected(pa+ents;(however,(such(reduc+ons(have(not(been(clearly(related(to(specific(therapeu+c(regimens.(

Study*Statement* We(analyzed(data(collected(over(42(months(in(the(HIV(Outpa+ent(Study.(During(this(period,(rates(of(chemoprophylaxis(against(opportunis+c(infec+on(remained(rela+vely(constant(even(while(paserns(of(an+retroviral(therapy(were(changing

Summary*Statement*

This(report(outlines(the(changes(in(death(rates(and(the(incidence(of(opportunis+c(infec+ons(in(a(large(group(of(HIVFinfected(outpa+ents,(many(of(whom(had(previously(received(extensive(treatment.

Among(the(few(diseases(claimed(to(occur(more(ogen(in(nonFsmokers(than(smokers(1(2(that(of(greatest(poten+al(importance(is(Alzheimer's(disease,(which(accounts(for(most(of(the(demen+as(of(later(life(in(Britain

Problem*Statement*

The(published(epidemiological(evidence,(although(sugges+ve(of(an(inverse(rela+on(with(smoking,(is(not(conclusive(either(about(Alzheimer's(disease(or(demen+a(in(general.(Much(of(the(evidence(derives(from(small(retrospec+ve(studies(of(uncertain(reliability,(many(of(which(excluded(vascular(demen+a.(Prospec+ve(studies,(in(which(smoking(habits(are(recorded(before(the(onset(of(demen+a,(should(be(more(informa+ve(about(the(overall(effects(of(smoking,(par+cularly(if(they(concern(large(numbers(and(prolonged(follow(up.(Only(a(few(such(studies(have,(however,(been(properly(reported((none(of(which(had(prolonged(follow(up)

Study*Statement*

We(sought(evidence(from(the(cohort(of(Bri+sh(doctors(who(have(been(followed(since(1951,(with(their(smoking(habits(reviewed(every(six(to(12(years.3(4(Many(have(died(from(or(with(some(type(of(demen+a(over(the(past(two(decades.

Summary*Statement*

Alcohol(was(first(implicated(as(a(possible(risk(factor(for(stroke(in(1725(1)(Several(epidemiological(studies(now(suggest(a(UFshaped(associa+on(between(alcohol(intake(and(stroke(2).

Problem*Statement*

Previous((studies(have(been(cri+cized(for(not(differen+a+ng(between(nondrinkers(who(were(lifelong(abstainers(and(those(who(had(given(up(drinking(3F7)(By(asking(specifically(about(previous(regular(drinking(habits(we(have(been(able(to((dis+nguish(between(the(two(groups.(The(level(of(alcohol(consump+on(at(which(this(possible(protec+ve(effect(is(lost(and(alcohol(becomes(a(risk(factor(for(stroke(are(unknown.

Study*Statement*

We(report(the(findings(of(a(caseFcontrol(study(that(examines(the(contribu+on(of(alcohol(to(the(risk(of(stroke(in(moderate(and(heavy(drinkers((both(currently(and(previously),(lifelong(abstainers((those(who(have(never(drunk(alcohol),(and(current(abstainers((those(who(had(formerly(been(regular(drinkers(but(who(currently(do(not(drink(alcohol),(using(validated(measures(of(alcohol(consump+on.

Summary*Statement*

Between(May(2009(and(May(2010,(Greece(experienced(two(waves(of(influenza(A(H1N1)2009(transmission

Problem*Statement*

Given(the(poten+al(for(worsening(in(the(clinical(severity(of(influenza(during(the(postFpandemic(influenza(season,(as(was(the(case(for(previous(influenza(pandemics([7F9],(it(was(cri+cal(to(con+nue(surveillance(with(a(focus(on(severe(cases(and(their(clinical(characteris+c

Descrip2on*of*the*Surveillance*System*

In(Greece,(influenza(is(annually(monitored(through(the(rou+ne(sen+nel(surveillance(system,(which(became(opera+onal(in(1999.(The(sen+nel(surveillance(system,(which(covers(approximately(three(percent(of(the(total(Greek(popula+on(in(the(2010/11(influenza(season,(provides(data(representa+ve(of(the(na+onal(popula+on

Summary*Statement*

This(report(summarises(data(from(influenza(surveillance(in(Greece(during(the(postFpandemic(2010/11(influenza(season.(

Materials(and(Methods(

•  Clearly(present/define(all(analysis(variables(•  Organize(into(logical(subsec+ons(that(illustrate(the(steps(you(took(to(collect,(organize,(and(analyze(the(data:(o  Study(popula+on(o  Defini+on(of(variables(o  Laboratory(methods/(epidemiological(inves+ga+on(o  Interven+on(

•  Describe(what(you(did,(not(what(you(found((Results)(•  Respect(chronology(•  Describe(the(original(methods(in(detail;(otherwise(give(references(

Purpose:(to(describe(how(you(collected,(organized(and(analyzed(data((relevant(to(the(study(purpose)(

Length(varies(depending(on(originality(of(methods( 73(

Materials(and(Methods(–(part1(Methods Study(design Present(key(elements(of(study(design(early(in(the(paper

Seing Describe(the(seing,(loca+ons,(and(relevant(dates,(including(periods(of(

recruitment,(exposure,(followFup,(and(data(collec+on

Par+cipants(and(

(a)(Cohort(study—Give(the(eligibility(criteria,(and(the(sources(and(

methods(of(selec+on(of(par+cipants.(Describe(methods(of(followFup(

CaseYcontrol(study—Give(the(eligibility(criteria,(and(the(sources(and(

methods(of(case(ascertainment(and(control(selec+on.(Give(the(ra+onale(

for(the(choice(of(cases(and(controls(

CrossYsec6onal(study—Give(the(eligibility(criteria,(and(the(sources(and(

methods(of(selec+on(of(par+cipants

(b)(Cohort(study—For(matched(studies,(give(matching(criteria(and(

number(of(exposed(and(unexposed(

CaseYcontrol(study—For(matched(studies,(give(matching(criteria(and(the(

number(of(controls(per(case 74(

Variables Clearly(define(all(outcomes,(exposures,(predictors,(poten+al(confounders,(and(effect(modifiers.(Give(diagnos+c(criteria,(if(applicable

Data(sources/(

measurement

(For(each(variable(of(interest,(give(sources(of(data(and(details(of(methods(of(assessment((measurement).(Describe(comparability(of(assessment(methods(if(there(is(more(than(one(group

Bias Describe(any(efforts(to(address(poten+al(sources(of(bias

Study(size Explain(how(the(study(size(was(arrived(at

Sta+s+cal(

methods

(a)(Describe(all(sta+s+cal(methods,(including(those(used(to(control(for(confounding (b)(Describe(any(methods(used(to(examine(subgroups(and(interac+ons (c)(Explain(how(missing(data(were(addressed (d)(Cohort(study—If(applicable,(explain(how(loss(to(followFup(was(addressed(CaseYcontrol(study—If(applicable,(explain(how(matching(of(cases(and(controls(was(addressed(CrossYsec6onal(study—If(applicable,(describe(analy+cal(methods(taking(account(of(sampling(strategy (e)(Describe(any(sensi+vity(analyses

Materials(and(Methods(–(part2(

Study(Design(

•  Observa+onal(or(Experimental(

•  Retrospec+ve(or(Prospec+ve(

Seing(and(Par+cipants(

•  Describe(the(study(popula+on(and(seing:(

•  Descrip+on(should(involve(relevant(demographic,(environmental,(diagnos+c,(comorbid(factors(

•  Defini+on(of(cohort/case(•  Exclusion/inclusion(criteria(•  How(was(consent(obtained?(•  Matching((in(caseFcontrol(study)(

Examples(of(seing(and(par+cipants(FF(cohort(

The(cohort(originally(comprised(34,439(male(doctors(on(the( Bri+sh( medical( register,( resident( in( the( United(Kingdom,(who(had( responded( to(a(ques+onnaire(about(their( smoking( habits( in( 1951.( Changes( in( such( habits(were(sought(in(1957,(1966,(1972,(1978,(1990,(and(1998,(and( other( personal( informa+on( was( sought( in( 1978,(1990,(and(1998.(In(1971,(follow(up(was(discon+nued(for(2459( subjects( (10.1%( of( the( survivors)( who(were( living(abroad( and( 218( (0.9%)( for( other( reasons.( Almost( all( of(the( remaining( survivors( have( con+nued( to( provide(informa+on(about(their(smoking(habits*.(

Smoking(and(demen6a(in(male(Bri6sh(doctors:(prospec6ve(study((

Examples(of(seing(and(par+cipants(–((case(control(

Cases*Three(hundred(sixtyFfour(consecu+ve(pa+ents(hospitalized(for(acute( stroke( in(Newcastle(upon(Tyne(between(August(1989( and( July( 1990( formed( the( study( popula+on.( No(pa+ent( refused( to( take( part( in( the( study.( Pa+ents( were(iden+fied(by(daily(contact(with(the(resident(medical(officer(and(completeness(of(case(ascertainment(was(checked(with(data( from(the(medical( records(department(at(each(of( the(three( par+cipa+ng( hospitals( (Freeman( Hospital,( Royal(Victoria( Infirmary,( and( Newcastle( General( Hospital)(Pa6ents( with( primary( subarachnoid( hemorrhage( were(excluded.(

Alcohol(and(stroke.(A(caseYcontrol(study(of(drinking(habits(past(

and(present((

Examples(of(seing(and(par+cipants(–((case(control((con+nued)(

Controls*Three(hundred(sixtyFfour(community(control(subjects(were(matched(for(age,(sex,(and(family(doctor.(Control(subjects(were(the(next(unrelated(matching(individual(to(the(case(in(

the(family(doctor(register.(Control(subjects(

with(a(previous(history(of(stroke(were(

excluded.(

Examples(of(seing(and(par+cipants(–((cross(sec+onal(

The(1997(obligatory(health(examina+on(before(school(entry( evaluated( 134,577( children( in( Bavaria,( southern(Germany.( At( the( examina+on,( the( parents( of( 13,345(children( seen( in( two( rural( regions( were( asked( to(complete(a(ques+onnaire(about( risk( factors( for(atopic(diseases.( Data( collected( by( this( ques+onnaire( were(linked( with( the( data( from( the( school( health(examina+on.( Our( analysis( was( confined( to( children(aged(5(and(6(who(had(German(na+onality.(

Breast(feeding(and(obesity:(cross(sec6onal(study(

Examples(of(seing(and(par+cipants(–((cross(sec+onal(

The(study(took(place(at(the(an+retroviral(therapy(clinic(of(Queen(Elizabeth(Central(Hospital(in(Blantyre,(Malawi,(from(January(2006(to(April( 2007.( Blantyre( is( the(major( commercial( city( of(Malawi,(with(a(popula+on(of(1,000,000(and(an(es+mated(HIV(prevalence(of(27%(in(adults(in(2004.Eligible(par+cipants(were(all(adults(aged(18( or( over( with( HIV( who( met( the( eligibility( criteria( for(an+retroviral( therapy( according( to( the( Malawian( na+onal( HIV(treatment( guidelines( (WHO( clinical( stage( III( or( IV( or( any(WHO(stage( with( a( CD4( count( <250/mm3)( and( who( were( star+ng(treatment( with( a( BMI( <18.5.( Exclusion( criteria( were( pregnancy(and( lacta6on(or(par6cipa6on( in(another( supplementary( feeding(program(

Supplementary(feeding(with(either(readyYtoYuse(for6fied(spread(or(cornYsoy(blend(in(

wasted(adults(star6ng(an6retroviral(therapy(in(Malawi:(randomised,(inves6gator(

blinded,(controlled(trial(

Seing(and(par+cipantsFSurveillance(

(ONGOING(OUTBREAK(OF(WEST(NILE(VIRUS(INFECTION(IN(HUMANS,(GREECE,(JULY(TO(AUGUST(2011(

CaseZDefini2on*•  (A(confirmed(case(is(defined(as(a(person(mee+ng(any(of(the(

following(clinical(criteria:(encephali+s,(meningi+s,(fever(without(specific(diagnosis(and(at(least(one(of(the(four(laboratory(criteria:((i)(isola+on(of(WNV(from(blood(or(cerebrospinal(fluid((CSF),((ii)(detec+on(of(WNV(nucleic(acid(in(blood(or(CSF,((iii)(WNVFspecific(an+body(response((IgM)(in(CSF,(and((iv)(WNV(IgM(high(+tre,(and(detec+on(of(WNV(IgG,(and(confirma+on(by(neutralisa+on.(

Study(Variables(

•  Specify(unit(of(measurement((if(applicable)(

•  Quan+fy(exposure(•  Variable(transforma+ons(

•  Criteria(for(defini+ons(•  Units(of(+me(and(special(categories(

Study(Variables((examples)(

The( children's( height( and( weight( were( measured( as(part(of(the(rou+ne(examina+on.(Body(mass(index(was(calculated( as( weight( (kg)/(height( (m)2).( The( age(specific(and(sex(specific(distribu+on(of(the(body(mass(index( among( all( children( with( German( na+onality( in(Bavaria,(which(had(been(inves+gated(during(the(1997(school(health(examina+on,(was(used(as(the(reference(for( being( overweight( (defined( as( body( mass( index(

above(the(90th(cen6le)(or(obese((defined(as(body(mass(

index( above( the( 97th( cen6le)( because( these( cen+les(were(higher(than(other(European(reference(values.((

Study(Variables((examples)((

Hypertension( was( iden6fied( by( medical( history( or(

posi6ve(screening(results((systolic(pressure(≥140(mm(

Hg).(PreYhypertension((asystolic(pressure(of(120–139(mm( Hg)( and( preYdiabetes( (a( fas6ng( blood( glucose(concentra6on( of( 6.1–6.9(mmol/L)( were( defined( on(the( basis( of( screened( laboratory( results.( Individuals(were( regarded( as( regular( alcohol( drinkers( if( they(consumed( two( or( more( alcoholic( drinks( a( day( on(three(or(more(days(a(week,(and(occasional(drinkers(if(they(consumed(less(than(regular(drinkers.(

Study(Variables((con+nued)(

Data( from( clinic( visits( were( used( to( calculate( the( number( of( days( of(observa6on(per(quarter( for(each(pa+ent( in(each(of( four(categories(of(prescribed(an+retroviral(therapy.(These(categories,(in(increasing(order(of(intensity,(were(no(an+retroviral(therapy,(monotherapy,(combina+on(therapy( without( a( protease( inhibitor,( and( combina+on( therapy( that(included(a(protease(inhibitor.(((The( data( collected( for( each( case,( using( a( standardised( form,( were:(demographic( characteris+cs( (age,( sex),( dates( of( admission( to( the(hospital( and( the( ICU,( the(+me( course( of( illness( including( the( date( of(symptom( onset,( underlying( condi+ons,( complica+ons,( use( of(mechanical( ven+la+on( support( (dates( of( intuba+on( and( extuba+on),(and(an+viral(treatment(

Data(Sources/Management(

•  How(the(data(were(collected(•  If(it(was(part(of(the(registry,(describe:(

– Original(purpose(of(the(database(– How(large(the(database(is,(+meliness(– Valida+on,(quality(checks(– Error(rate(

•  Database(sogware/hardware(•  For(surveillance(paper(–(a(diagram(of(the(surveillance(system(is(preferred((

Pa+ents( (with( a( close( rela+ve( or( significant( other(

when( possible)( were( interviewed( and( examined( by(

H.R.( (79%)( or( P.D.A.( within( 48( hours( of(

hospitaliza+on.( Control( subjects(were( interviewed( in(

their(homes(by(H.R.((also(with(a(rela+ve(or(significant(

other( when( possible).( InterFobserver( valida+on(

studies( between( the( two( interviewers( were( carried(

out.( The( propor+on( of( agreement( between( two(

observers,(K,(was(0.68.((

Drinking( frequency( was( recorded( as( a( categorical(variable,( whereas( past( and( present( amounts( of(alcohol( consump+on,( dura+on( of( abs+nence,( and(heavy( drinking( were( recorded( as( con+nuous(variables.( Data( were( transferred( to( Northumbrian(

University's( Mul6ple( Access( Computer( (NUMAC).(

Following( verifica6on( procedures( to( ensure( accurate(

transcrip6on,(data(were(analyzed(using(spssYx((SPSSYX(

Batch(System,(SPSS(Inc.,(Chicago,(Illinois).(

•  Informa6on(in(five(general(categories(has(been(abstracted(

from(the(chart(for(each(outpa6ent(visit(and(entered(

electronically(by(trained(data(abstracters;(the(data(are(

compiled(centrally,(reviewed,(and(corrected(before(being(

included(in(the(data(base.(Because(the(study(physicians(are(

the(source(of(primary(care(for(these(pa+ents,(all(symptoms,(

diagnoses,(and(treatments(since(the(previous(visit,(are(noted(

at(each(clinic(visit.(The(categories(of(informa+on(are(as(

follows:(demographic(characteris+cs;(symptoms;(diagnosed(

diseases;(medica+ons(prescribed;(and(laboratory(values.((

Study(Size(

•  Specify(the(null(hypothesis(and(whether(it(is(one(or(twoFsided(

•  Specify(the(minimum(difference(in(response(variable(that(is(considered(to(be(clinically(important(

•  Specify(power(and(alpha(level(for(calcula+ng(sample(size(

Examples(

To( detect( a( reduc+on( in( PHS( (postopera+ve(hospital( stay)(of(3$days$ (SD(5(days),(which( is( in(agreement(with( the( study(of( Lobo(et(al.(with(a(twoFsided(5%( significance( level( and(a(power(of(80%,(a(sample(size(of(50(pa+ents(per(group(was(necessary,(given(an(an+cipated(dropout( rate(of(10%.( To( recruit( this( number( of( pa+ents,( a( 12Fmonth(inclusion(period(was(an+cipated(

Examples(

Based(on(an(expected( incidence(of( the(primary(composite(endpoint(of(11%(at(2.25(years(in(the(placebo( group,( we( calculated( that( we( would(need(950(primary(endpoint(events(and(a(sample(size( of( 9650( pa+ents( to( give( 90%( power( to(detect( a( significant( difference( between(ivabradine(and(placebo,(corresponding(to(a(19%$reduc;on$of$rela;ve$risk$(with(a(twoFsided(type(1(error(of(5%)(

Randomiza+on(–((Randomized(controlled(trials((RCT)(

Par+cipants( should( be( assigned( to(comparison( groups( in( the( trial( on( the(basis( of( a( chance( (random)( process(characterized(by(unpredictability(******(

(Randomized(controlled(trials((RCT)(FF(

examples(

•  Independent(pharmacists(dispensed(either(ac+ve(or(placebo(inhalers(according(to(a(computer(generated(randomiza+on(list(

(•  For(alloca+on(of(the(par+cipants,(a(computerFgenerated(list(of(random(numbers(was(used(

******(

Randomiza+on((con+nued)(

•  Randomiza+on(sequence(was(created(using(Stata(9.0((StataCorp,(College(Sta+on,(TX)(sta+s+cal(sogware(and(was(stra+fied(by(center(with(a(1:1(alloca+on(using(random(block(sizes(of(2,(4,(and(6(

(•  Par+cipants(were(randomly(assigned(following(simple(randomiza+on(procedures((computerized(random(numbers)(to(1(of(2(treatment(groups(

Randomiza+on(FF(Concealment(

A( generated( alloca+on( schedule( should( be(implemented(by(using(alloca+on(concealment,(a( c r i+ca l( mechan i sm( that( p revents(foreknowledge( of( treatment( assignment( and(thus(shields(those(who(enroll(par+cipants(from(being( influenced( by( this( knowledge.( The(decision( to( accept( or( reject( a( par+cipant(should(be(made,(and(informed(consent(should(be(obtained(from(the(par+cipant,(in(ignorance(of(the(next(assignment(in(the(sequence(

Randomiza+on((concealment)(

The(doxycycline(and(placebo(were(in(capsule(form(and(iden+cal(in(appearance.(They(were(prepackaged( in( bosles( and( consecu+vely(numbered(for(each(woman(according(to(the(randomiza+on( schedule.( Each( woman( was(assigned( an( order( number( and( received( the(capsules( in( the( corresponding( preFpacked(bosle(

Blinding((RCTs)(

The( term( “blinding”( or( “masking”( refers( to(withholding( informa+on( about( the( assigned(interven+ons(from(people(involved(in(the(trial(who(may( poten+ally( be( influenced( by( this( knowledge.(Blinding( is( an( important( safeguard( against( bias,(par+cularly(when(assessing(subjec+ve(outcomes.(EXAMPLE:(Whereas( pa+ents( and(physicians( allocated( to( the(interven+on( group( were( aware( of( the( allocated(arm,( outcome( assessors( and( data( analysts( were(kept(blinded(to(the(alloca+on.(

Laboratory(Methods(Surveillance)(

Serum(and(CSF(specimens(were(tested(for(the(presence(of(WNVFspecific(IgM(and(IgG(an+bodies(using(commercial(ELISA(kits((WNV(IgM(capture(DxSelect(and(WNV(IgG(DxSelect,(Focus(Diagnos+cs(Inc,(Cypress,(CA,(USA).(WNV(posi+ve(specimens(were(also(tested(for(the(presence(of(other(flaviviruses:(+ckFborne(encephali+s(virus((TBEV)(and(dengue(virus((DENV).(

Sta+s+cal(Methods(

•  Describe(all(sta+s+cal(methods,(including(those(used(to(control(for(confounding(

•  Describe(the(comparisons(to(be(made(and(the(sta+s+cal(procedures(to(be(used(for(making(them(

•  State(whether(the(sta+s+cal(analysis(will(be(on(the(basis(of(inten+onFtoFtreat(

•  Control(for(mul+ple(tes+ng(problem(•  Report(hypothesis(power(and(level((if(it(is(not(reported(in(sampling(sec+on)(

•  Report(all(required(pFvalues(and(confidence(intervals(

Sick *******************Not*sick*

***************Expo

sed********Not*exposed

****Cases * *Controls*

No*history*of*disease******History*of*d

isease*

Assessment(of(risk(ra+on(

In(case(control(study(the(risk(ra+on(has(no(outcome,(odds(ra+on(used(instead(

Repor+ng(sta+s+cal(methods(in((CrossFSec+onal(studies(

•  Standard(descrip+ve(sta+s+cs:(FSimple(prevalence(calcula+on(

•  Prevalence(of(disease(or(prevalence(of(exposure(

•  Regression(to(control(confounders(

CrossFsec+onal(study(example:(Sta+s+cal(Methods(

Pa+ent( characteris+cs,( adjusted( for( stone( history(and(age,(were(compared(using( linear(regression(for(con+nuous( covariates( and( logis6c( regression( for(categorical( covariates.( Mul6ple( linear( regression(was(used(to(compare(mean(es+mated(GFR(between(stone( formers( and( nonFstone( formers.( Covariates(iden+fied( as( poten+al( confounders( in( the(rela+onship( between( es+mated( GFR( and( stone(history(were(adjusted(for.(Mul6plica6ve(interac6ons(between( stone( history( and( age,( gender,( race,(diabetes,(and(BMI(were(formally(tested.((

CrossFsec+onal(study(example:(Sta+s+cal(Methods(

Mul6nomial(logis6c(regression(was(used(to(compare(the( rela+ve( risk( of( having( an( es+mated( GFR( in( a(lower( category( rela+ve( to( the( highest( category(between( persons( with( and( without( nephrolithiasis.(Model(based(es+mates(are(reported(as(rela6ve(risk(ra6os( comparing( stone( formers( with( nonFstone(formers.( Adjustment( covariates( included( in( the(mul+nomial(logis+c(regression(included(age,(gender,(race,( BMI,( systolic( blood( pressure,( HbA1c,( diabetes,(history( of( cardiovascular( disease,( smoking( status,(health( insurance( status,( and( use( of( prescrip+on(diure+cs.(

CrossFsec+onal(study(example(Sta+s+cal(Methods(

•  The(prevalence(of(overweight(and(obese(children(were(calculated(according(to(the(dura+on(of(breast(feeding.(The(appropriate(χ2$tests$were(used(to(compare(several(items(in(breasÜed(and(nonFbreasÜed(children(and(their(associa+on(with(the(child(being(overweight(or(obese.(Logis6c(regression(models(were(used(to(assess(the(impact(of(variables(that(were(significantly(associated((P<0.05)(with(both(breast(feeding(and(being(overweight(or(obese(Confounding(was(assumed(to(have(occurred(if(the(odds(ra6o(changed(by(≥10%.(Confounders(and(independent(risk(factors(were(included(in(the(final(logis6c(regression(model.(All(calcula+ons(were(carried(out(with(the(SAS(sogware(package,(version(6.12.(

Sta+s+cal(Methods((CaseFcontrol)(

•  Comparing(groups:(– Nominal((chiFsquared(or(McNemar’s(test)(– Ordinal((Wilcoxon,(signedFrank,(KruskalFWallis,(ANOVA)(

–  Con+nuous((tFtest,(ANOVA)(•  Odds(ra+os(–(strength(of(associa+on(between(exposure(and(disease(is(commonly(measure(by(an(OR(

•  Logis+c(Regression:(to(make(inference(on(exposureFdisease(associa+on(while(adjus+ng(for(covariates(

Repor+ng(Sta+s+cal(Methods(in(CaseFControl(Study(

The(MannYWhitney(U(test(was(used(for(between(group(analyses(of(nonparametric(data,(the(standard(χ2(test(when(appropriate(for(discrete(variables,(and(McNemar's(χ2(test(to(compare(discordant(pairs.(The(odds(ra6o((OR)(with(95%(confidence(intervals((CIs)(was(used(as(an(es+mate(of(risk.(LogFlinear(analysis(was(used(to(calculate(the(adjusted(odds(ra+o(for(poten+al(confounding(variables.(

Repor+ng(Sta+s+cal(Methods(in(Cohort(Studies(and(Clinical(Trials(

•  TimeFtoFevent(data:(Survival(func+ons(–  Describe(censored(data((–  Confirm(that(requirements(have(been(met(

•  KaplanFMeier(analysis(•  Specify(methods(to(compare(two(or(more(survival(

curves(logFrank(or(Wilcoxon)(•  Hazard(ra+o(•  Cox(Propor+onal(Hazards(Model(

–  Report(measure(of(risk(for(each(variable(•  Repeated(measures(for(mul+ple(+me(points)(•  ANCOVA(for(primary(and(secondary(endFpoints(•  Number(of(end(points((

Repor+ng(Sta+s+cal(Methods(in(Cohort(Studies(and(RCTs(

As(preFspecified,(efficacy(analyses(were(performed(with( the( use( of( a( modified( inten+onFtoFtreat(approach,(which(included(the(randomized(pa+ents(and( the( endFpoint( events( that( occurred( ager(randomiza+on(and(no(later(than(the(comple+on(of(the(treatment(phase(of(the(study((i.e.,(the(globalFtreatment( end( date),( 30( days( ager( early(permanent( discon+nua+on( of( the( study( drug,( or(30(days( ager( randomiza+on( for(pa+ents(who(did(not(receive(a(study(drug(

Repor+ng(Sta+s+cal(Methods(in(Cohort(Studies(and(RCTs((con+nued)(

We(used(hazard(ra6os(and(twoFsided(95%(confidence(intervals(to( compare( the( study( groups.( Rates( of( the( end( points( were(expressed( as( Kaplan–Meier( es+mates( through( 24( months.(Tes+ng(was(preFspecified(to(occur(between(the(combinedFdose(group(for(rivaroxaban(and(placebo(at(an(alpha(level(of(0.05(on(the( basis( of( the( logYrank( test,( stra+fied( according( to( the(inten+on(to(use(a(thienopyridine.(If(this(comparison(significantly(favored(rivaroxaban,(then(each(of(the(two(doses(of(rivaroxaban(was( simultaneously( compared(with( placebo(with( the( use( of( a(similar( stra+fied( logFrank( test( at( an( alpha( level( of( 0.05(on( the(basis( of( the( closed( tes+ng( procedure.( Results( were( examined(according( to( major( subgroups( for( general( consistency( of(treatment(effect,(and(interac+on(tes+ng(was(performed.(

Repor+ng(Sta+s+cal(Methods(in(Randomized(Controlled(Experiments(

The( primary( endpoint( was( change( in(bodyweight(during(the(20(weeks(of( the(study(in( the( inten+onFtoFtreat( popula+on( …(Secondary(efficacy(endpoints( included(change(in( waist( circumference,( systolic( and( diastolic(blood( pressure,( prevalence( of( metabolic(syndrome(…(

Repor+ng(Sta+s+cal(Methods(in(Randomized(Controlled(Experiments(

We( used( an( analysis* of* covariance* (ANCOVA)( for(the(primary(endpoint(and(for(secondary(endpoints(waist( circumference,( blood( pressure,( and( pa+entFreported( outcome( scores;( this( was( supplemented(by( a( repeated( measures( analysis.( The( ANCOVA(model( included( treatment,( country,( and( sex( as(fixed( effects,( and( bodyweight( at( randomiza+on( as(covariate.( We( aimed( to( assess( whether( data(provided(evidence(of(superiority(of(each(liraglu+de(dose( to(placebo( (primary(objec+ve)(and( to(orlistat((secondary(objec+ve(

Repor+ng(Sta+s+cal(Methods(in(Cohort(Studies(and(RCTs(

We( calculated( hazard( ra6os( (HR)( to( compare( mortality(risks( between( individuals( in( different( exercise( groups((grouped(by(volume(of(exercise)(and(those(in(the(inac+ve(group.( We( used( a( Cox( propor6onate( model( to( analyze(categorical(and(con+nuous(variables(…((The( life( table( method( was( used( to( es+mate( life(expectancy.(We(calculated(adjusted(odds(ra+os(and(95%( CIs( by( comparing( the( propor+on( of( individuals(mee+ng(ac+vity(recommenda+ons(with(the(propor+on(of(those(who(were(inac+ve(within(each(characteris+c(group(

Sta+s+cal(Methods(F(Surveillance(

•  Exploratory(data(analysis:(–  Incidence(by(age,(sex,(geography(–  Trends(

•  Severity(factors(•  Group(comparisons((

–  Two(sample(tests,(etc.(•  Event(detec+on(

–  Detec+on(methods(+me(series/spa+otemporal)(–  Timeliness(–  Sensi+vity/Specificity((

•  For(early(detec+on(of(localized(clusters(of(dead((birds,(we(used(a(prospec+ve(surveillance(system((that(is(based(on(the(spa+al(scan(sta+s+c((9).(This((scan(sta+s+c(uses(a(circular(window(to(represent(poten+al(geographic(clusters.(

•  Temporal(trends(in(annual(no+fica+on(rates(of(salmonellosis,(infec+ous(diarrhoea(and(outbreaks(of(foodFborne(diseases(were(assessed(using(the(Cuzick(test([9].(Annual(rates(of(salmonellosis(and(infec+ous(diarrhoea(were(compared(between(the(sexes(using(the(Mann–Whitney(test(and(among(age(groups(using(the(Kruskal–Wallis(test.(Post(hoc(paired(comparisons(ager(the(Kruskal–Wallis(test(were(tested(using(the(Mann–Whitney(test(on(each(pair(of(age(group(and(pFvalue(adjustment(according(to(Bonferroni’s(method([10](

Sta+s+cal(Methods(F(Surveillance(

Results(

•  Start(with(the(tables(and(figures.((Write(the(text(later.(o  Use(tables(to(highlight(individual(values(o  Use(figures(to(highlight(trends(and(rela+onships(

•  Text(supplements(and(reinforces(tables(and(figures(o  Summarize/emphasize(highlights(o  Fill(in(gaps((ogen(minor)(

•  Present(results(in(a(logical(sequence(•  Describe(what(you(found,(not(what(you(did((Methods)(•  Consider(subFsec+ons(similar(to(the(ones(in(Methods(•  Look(to(published(ar+cles(for(poten+al(templates(

Purpose:(to(describe(the(results(of(data(analysis(that(are(relevant(to(the(study(purpose(

Results((con+nued)(Tables/Figures(•  Check(your(math;(provide(consistent(row(or(column(

summa+on.(•  Keep(lines(to(a(minimum;(avoid(ver+cal(lines.(•  Use(footnotes(to(clarify(points(of(poten+al(ambiguity.(•  Check(headings,(labels(of(rows/columns/axes,(and(footnotes(Text(•  Highlight(key(rela+onships(between(dependent/independent(

variables.(•  Present(a(logical(sequence:((

o  in(parallel(with(methods((consider(similar(subheadings)(o  background(data(→(descrip+ve(→(bivariate(→(mul+variate(

•  Make(sure(all(numbers(in(text(are(consistent(with(tables/figures.(

(($$$$( Oaen(requires(just(three(paragraphs(+(three(tables/figures(

Tables(versus(Figures(

Tables:(beser(to(use(when(knowledge(of(individual(values(or(sta+s+cs(are(more(important(than(trends(and(conceptual(understanding(

1.  Title(2.  Column/row(headings(

3.  Data(fields(4.  Footnotes(5.  Spanner(

Five(elements(of(a(table(

Table(Title:(Example(Example(1:(( (Sta+n(therapy(and(cancer(recurrence.(Example(2:((

(Effect(of(daily(oral(primvasta+n(or(dorvasta+n(on(the(4Fyear(odds(ra+o(for(the(recurrence(of(prostate(and(breast(cancer.(Example(3:(( (The(effect(of(daily(oral(primvasta+n(or(dorvasta+n(on(the(4Fyear(odds(ra+o((OR)(for(the(recurrence(of(prostate(and(breast(cancer(shows(a(3Ffold(lower((P(=(0.002)(OR(for(the(recurrence(of(breast(cancer(for(pa+ents(receiving(primvasta+n((OR(=(2.3)(versus(dorvasta+n((OR(=(6.8).(

Tables(:(General(Recommenda+ons(

•  Indicate(missing(data(by(using(a(dash,(NA,(or(…(

•  Each(footnote(should(be(placed(on(a(separate(line(at(the(bosom(of(the(table(

•  Lesers((or(numbers,(or(symbols)(designa+ng(footnotes(should(be(ordered(alphabe+cally((or(numerically)(

•  The(symbol(designa+ng(a(footnote(that(applies(to(the(en+re(table(should(be(placed(ager(the(+tle(

Table(Alignment(

•  The(stubs(should(be(all(leg(jus+fied(•  In(the(columns/data(fields,(words(should(be(leg(jus+fied(and(whole(numbers(rightFjus+fied((

•  Data(fields(containing(decimal(points,(plus/minus(symbols,(slashes,(hyphens,(or(parentheses(should(be(aligned(on(these(elements.(

•  When(the(text(in(a(stub(wraps(to(a(second(line,(the(corresponding(data(field(should(align(with(the(top(line(of(the(stub.(

A.*Annual*per*capita*healthcare*expenditures.*

Expenditure,($(

Israel* 1971(

Madagascar* 36(

Sweden* 2828(

Yemen* 82(

Zimbabwe* 149(

B.*Annual*per*capita*healthcare*expenditures.*

Expenditure,($(

Israel* 1971(

Madagascar* 36(

Sweden* 2828(

Yemen* 82(

Zimbabwe* 149(

C.*Annual*per*capita*healthcare*expenditures.*

Expenditure,($(

Sweden* 2828(

Israel* 1971(

Zimbabwe* 149(

Yemen* 82(

Madagascar* 36(

Table(alignment(example(

Tables,(column(formats(example(

Mean (SD), mg/L

Mean ± SD, mg/L

Deviation from target, %

Pig serum 11.4 (2.1) 11.4 ± 2.1 14 Sheep serum 10.7 (1.4) 10.7 ± 1.4 7 Artificial serum 10.3 (0.8) 10.3 ± 0.8 3

Saline 10.1 (0.6) 10.1 ± 0.6 1 Human serum 9.9 (0.6) 9.9 ± 0.6 −1 Cow serum 9.6 (1.4) 9.6 ± 1.4 −4 Horse serum 8.9 (0.7) 8.9 ± 0.7 −11

Table 3. Phenytoin concentrations measured by immunoassay for matrices supplemented with 10 mg/L phenytoin.#

Two*different*styles**of*presen2ng*results**127(

What(is(the(right(size?(

•  60(characters(for(halfFpage,(120(for(full(•  For(a(2Fcolumn(journal,(110(characters(would(fit(onto(a(portraitFformased(page.(

•  Otherwise(journal(might(publish(landscape((•  ReForient(if(number(of(column(headings(:(row(headings(greater(2:1(

•  If(only(one(pFvalue(out(of(the(whole(column(is(significant(–(remove(and(place(a(not(in(a(footnote(

•  Use(abbrevia+ons(when(journals(permit(it(•  Split(into(2(

Example(:(Table(Too(Wide(

Age, years

Undifferentiated leukemia

Myeloblastic

leukemia, %

Promyelocytic

leukemia, %

Myelomonocytic

leukemia, %

Monocytic

leukemia, %

Erythroleukemia,

Microkaryoblasti

c leukemia

Megakaryoblastic leukemia

<21 91 80 85 81 82 73 62 52

21–40 89 83 79 77 68 61 57 41

41–60 74 62 68 59 40 37 31 24

>60 51 48 39 34 28 21 16 9

Table 5. Age-related 5-year survival for forms of acute myelogenous leukemia.#

Table,(reForiented(

AML type Age

<21 Years 21–40 Years 41–60 Years >60 Years

Undifferentiated, % 91 89 74 51

Myeloblastic, % 80 83 62 48

Promyelocytic, % 85 79 68 39

Myelomonocytic, % 51 48 39 34

Monocytic, % 82 68 40 28

Erythroleukemia, % 73 61 37 21

Microkaryoblastic, % 62 57 31 16

Megakaryoblastic, % 52 41 24 9

Table*7.(AgeFrelated(5Fyear(survival(for(forms(of(acute(myelogenous(leukemia((AML)(

Formaing(tables,(con+nued(

Study No. of patients

Leukocyte count, %a Day 0

Day 14

Day 21

Day 28

Day 56

Day 84

Wilkins and Potter, Refb11 M11;F11 100 97 — 84 — — 70

Pillsbury et al., Ref 12 M10;F18 100 100 81 — 76 — 64

Annesley et al., Ref 18 M27;F20 100 89 76 — 63 — 62

Kronnenberg and Stenmeyerson, Ref 20 M9;F7 100 103 95 — 88 69 —

Flowers and Peterson, Ref 25 M20;F23 100 101 96 93 89 86 98

Flloyd et al., Ref 26 M27;F23 100 95 — — 91 — 79

Robinson et al., Ref 27 M19;F20 100 — 100 — 96 — 94

Nowicki and Phillips, Ref 32 M15;F16 100 — 92 — 82 74 —

Table 6. Previous studies of leukocyte reduction during kelvac therapy in patients with chronic myelogenous leukemia.#

Are(these((columns(necessary?(

Figures(

•  Proper+es(of(a(good(graph:(– Draws(asen+on(to(the(data(and(not(the(graph(– The(symbols(and(connec+ng(lines(are(easy(to(read(

– Axis(number(and(labels(are(easy(to(read(

– The(lengths(of(the(two(axes(are(balance(((1:1.3)(– The(scales(used(on(each(axis(match(the(range(

– Tick(marks(are(used(appropriately(

– The(legend(is(clear(and(concise(– SelfFsufficient((

– The(data(deserve(to(be(graphed(132(

Common(Mistakes(

Plasma*vs.*serum*sodium*for*paired*specimens*from*150*pa2ents.*(A),(xF(and(yFaxis(scales(of(0–165(mmol/L;(((B),(xF(and(yFaxis(scales(of(120–170(mmol/L;(((C),(Bland–Altman(plot.(

Using(appropriate(axis(interval(

Why(include(this(graph?(

Results(vs.(Data(Figure(1(shows(the(survival(rates(following(diagnosis(and(ini+a+on(of(treatment(in(the(3(treatment(groups.(At(6(months(the(survival(rates(were(95%(for(the(A(group,(91%(for(the(B(group,(and(39%(for(the(radia+onFtreated(group.(At(12(months(the(rates(were(83%,(69%,(and(23%;,(at(18(months(74%,(17%,(and(15%;(and(at(24(months(were(70%,(11%,(and(9%.(

Data*but*no*results*

Figure(1(shows(the(survival(rates(following(diagnosis(and(ini+a+on(of(treatment(in(the(3(treatment(groups.(At(6(months(the(survival(rates(were(significantly(higher(in(the(A(and(B(treatment(groups(compared(with(the(radia+onFtreatment(group.(At(12,(18,(and(24(months(the(survival(rates(in(the(A(group(exceeded(those(of(both(the(B(and(radia+onFtreatment(groups.(

Results,*but*no*data*

Results(vs.(Data(

Six(months(ager(diagnosis(and( ini+a+on(of(treatment,(the(survival(rates(for(the(A(and( B( groups( were( 2.4( and( 2.3( +mes(higher,( respec+vely,( than( the( radia+on(treatment( group( (both( P( <( 0.001),( but(survival( rates( were( not( found( to( differ(between( the( A( and( B( groups( (P( =( 0.56)((Figure( 1).( By( 12( months,( however,(pa+ent( survival( in( the( A( group( was( 1.2(+mes( higher( than( in( the( B( group( (P( =(0.031),( and( 4.3( and( 6.4( +mes( higher( at(18(and(24(months((both(P(<0.001).(

Results(and(only(the(Results(

We( compared( the( death( rates( for( the( 262( healthy( controls(

with(those(of(the(203(conges6ve(heart(failure(pa6ents(over(a(

2Yyear( period.( Survival( curves( were( generated( with( the(

Masterson( mortality( index( formula.( The( conges+ve( heart(failure(group(was(found(to(have(a(significantly(higher(shortFterm(mortality(rate.(

When( the( 2Fyear( survival( curves( for( healthy( controls( and(conges+ve( heart( failure( pa+ents( were( compared,( the(conges+ve( heart( failure( group( was( found( to( have( a(significantly(higher(shortFterm(mortality(rate.(

Using(modern(graphics(and(visualiza+on(

PennFstate(university:(mul+Fpurpose(map(with(+me(and(spa+al(flu(cases(distribu+on(support(

Using(modern(graphics(and(visualiza+on(

Red(–(anger,(blue(–(dissa+sfac+on,(yellow(–(joy,(emo+ons(in(blog(community(

Использование(современных(графиков(и(методов(визуализации(

Popula+on(distribu+on(by(countries(

Results(F(Key(Tables(•  Study(flow(•  Comparison(between(study(and(control(group(at(baseline((so(

groups(are(comparable)(–  Give(characteris+cs(of(study(par+cipants((e.g.(demographic,(clinical,(social)(and(informa+on(on(exposures(and(poten+al(confounders(

–  (Cohort(study—Summarise(followFup(+me((e.g.,(average(and(total(amount)(

•  Primary(comparison(table(–  (cohort,(RCT)(Report(absolute((and(rela+ve)(differences(for(primary(endpoints(

–  (cohort,(RCT)(Report(95%(CI(for(primary(endpoints(–  (caseFcontrol)Report(numbers(in(each(exposure(category,(or(summary(measures(of(exposure(

–  (crossFsec+onal)(Report(numbers(of(outcome(events(or(summary(measures(

Results(F(Key(Tables((con+nued)(•  Main(Results:(

– (Give(unadjusted(es+mates(and,(if(applicable,(confounderFadjusted(es+mates(and(their(precision((e.g.,(95%(confidence(interval).(Make(clear(which(confounders(were(adjusted(for(and(why(they(were(included(

– (Report(category(boundaries(when(con+nuous(variables(were(categorized(

– (If(relevant,(consider(transla+ng(es+mates(of(rela+ve(risk(into(absolute(risk(for(a(meaningful(+me(period(

Results(Checklist(Par+cipants( Report(number(of(individuals(at(each(

stage(of(the(study(• Consider(flow(diagram(• Give(reasons(for(nonFpar+cipa+on(

Baseline(Data( Baseline(demographic(and(clinical(characteris+cs(for(each(group(

Variables/Outcomes( Report(numbers(of(outcome(events(or(summary(measures(over(+me(

Main(results( Give(unadjusted(es+mates(and(if(applicable,(confounderFadjusted(es+mates(and(their(precision.((

Adverse(effects((for(Experimental(Designs)(

Readers(need(informa+on(on(poten+al(harm(as(well(as(benefit(

Results(examples(

T h e( n e x t ( s e v e r a l ( s l i d e s(demonstrate( different( ways( to(present(results(

Results:(CONSORT(Flow(

Eligible((NonFeligible(Declined(

Alloca+on(using(randomiza+on(scheme(

FollowFup(

Included(in(analysis(

Results(–(sample(study(flow(

Results(–(baseline(comparison(

Results:(Primary(outcome((RCT)(

Results(–(primary(outcomes((RCT)(

Results:(Primary(outcome((RCT)(

Results(–(primary(outcome((cohort)(

Primary(outcome((alterna+ve(figure)(

Primary(Efficacy(End(Point((RCT)(

Results(–(primary(outcome((CrossFsec+onal) ((

Regression(with(primary(outcomes((CrossFsec+onal(study)(

Results(–(Regression(with(OddsFRa+os(

ResultsFReport(Adverse(Effects(

“The( propor+on(of( pa+ents( experiencing( any( adverse( event(was( similar( between( the( rBPI21( [recombinant( bactericidal/permeabilityFincreasing( protein]( and( placebo( groups:( 168((88.4%)( of( 190( and( 180( (88.7%)( of( 203,( respec+vely,( and( it(was( lower( in( pa+ents( treated( with( rBPI21( than( in( those(treated( with( placebo( for( 11( of( 12( body( systems( …( the(propor+on(of( pa+ents( experiencing( a( severe( adverse( event,(as( judged(by( the( inves+gators,(was(numerically( lower( in( the(rBPI21( group( than( the( placebo( group:( 53( (27.9%)( of( 190(versus( 74( (36.5%)( of( 203( pa+ents,( respec+vely.( There(were(only( three( serious( adverse( events( reported( as( drugFrelated(and(they(all(occurred(in(the(placebo(group.”(

Discussion(

•  Dis+ll(the(essence(of(your(study(o  ReFstate(key(results(o  State(main(conclusion(

! Be(clear(about(why(results(support(the(conclusion(! Maintain(connec+on(with(the(purpose(of(the(study(

•  Interpret(your(study(in(the(context(of(the(literature(o  Compare(with(results(of/methods(used(in(related(studies(o  Emphasize(strengths(of(your(study(and(what(is(new(

•  State(limita+ons/caveats((frankly,(without(apology)(•  Make(recommenda+ons(

o  Changes(in(prac+ce/policy(o  Future(studies,(including(some(specifics((e.g.(study(method)(

Purpose:(to(interpret(your(results(and(jus+fy(your(interpreta+on(

Oaen(requires(just(four(or(five(paragraphs(160(

Discussion(Checklist(Dis2ll*the*essence*of*study*

a.   Restate*key*results*b.   State*main*conclusion*

Z*Be*clear*about*why*results*support*the*conclusion.*Z*Maintain*connec2on*with*purpose*of*the*study.

Interpret*your*study*in*the*context*of*the*literature*a.   Compare*with*results*of/methods*used*in*related*studies*b.   Emphasize*strengths*of*your*study,*and*what*is*new

State*limita2ons/caveats*(use*examples)*Discuss*limita2ons*of*the*study,*taking*into*account*sources*of*poten2al*bias*or*imprecision.*Discuss*both*direc2on*and*magnitude*of*any*poten2al*bias

Make*recommenda2ons*a.   changes*in*prac2ce/policy*b.   future*studies,*including*some*specifics*(e.g.*study*method)

Discussion((Examples)(During(periods(of(seasonal(influenza(ac+vity,(we(found(moderately(ac+ve((1.5–2.9(METs/day)(and(ac+ve((≥3.0(METs/day)(individuals(to(be(approximately(15%(less(likely(to(have(an(influenzaFcoded(physician(office(or(emergency(department(visit(compared(to(inac+ve(individuals.(When(stra+fied(by(age,(we(observed(similar(findings(among(individuals(<65(years(but(not(≥65(years((((Among(individuals(<65(years,(moderately(ac+ve(and(ac+ve(individuals(were(not(more(likely(than(inac+ve(individuals(to(visit(physicians(for(nonFinfluenzaFrelated(condi+ons(such(as(derma++s(or(periodic(health(examina+ons(during(influenza(season…(

KEY(RESULTS(

MAIN(CONCLUSIONS(

Discussion((Examples)(

Aging( is( linked( to( declines( in( the( ability( to( defend(against(pathogens([40],(and(has(been(associated(with(increased( morbidity( and( mortality( from( infec+ous(diseases( in( the( elderly( [40]–[41].( Addi+onally,( ageFrelated( declines( in( immune( response( to( influenza(vaccines( are( well( documented( [42]–[44].( The(reduced(immune(func+on(of(the(elderly(may(prevent(them( from( receiving( any( immune( system( benefits(from( physical( ac+vity.( [Comparison* with* other*studies]*

Discussion((Examples)(To( our( knowledge,( this( is( the( first( epidemiologic( study( that( has(

examined( the( rela6onship( between( physical( ac6vity( and(

influenzaYrelated(morbidity(during( seasonal( influenza(epidemics.(

Previous(studies(have(mostly(focused(on(upper(respiratory(tract(infec+ons( (URTIs)(with( an( emphasis( on( athletes( [4],( and( only( a(few( focused( on( the( general( popula+on( [12],( [19],( [45].( Our(finding(of(a(15%(reduc+on(in(influenzaFcoded(outpa+ent(visits(is(similar( to( the( 20%( reduc+on( in( URTIs( observed( in( popula+onFbased( studies,( although( those( studies( used( selfFreported(outcome(measures([12],([19],([45].(Only(one(other(study(assessed(the(associa6on(between(physical(ac6vity(and( influenza,(and( the(

outcome( was( influenzaYassociated( mortality( [9].( Although( a(

beneficial(effect(was(found,(our(study(suggests(a(protec6ve(effect(

at(a(much(earlier(stage(than(mortality.(164(

Discussion((Examples)(F(limita+ons(

This(study(had(several(limita+ons.(First,(our(outcome(

measure(was(influenzaYcoded(outpa6ent(visits(rather(

than(laboratoryYconfirmed(influenza(infec6ons,(which(would(be(the(most(ideal(outcome(measure(

A(second(limita+on(is(that(measurement(of(physical(

ac6vity(and(certain(covariates(relied(on(selfYreport,(and(verifica6on(of(subject(responses(was(not(possible(

(First,(we(are(limited(in(our(ability(to(adequately(es+mate(an(associa+on(between(stone(history(and(renal(func+on(in(young(adults(due(to(a(lack(of(data(on(stone(formers(less(than(age(30(

Discussion(F(Recommenda+ons(

Future( research( should( ideally( use( laboratoryFconfirmed( influenza( outcomes( to( confirm( the(associa+on( between( physical( ac+vity( and(influenza(infec+on.(Public(health(authori+es(and(clinicians(should(work(toward(a(common(goal(of(increasing( physical( ac+vity( and( the( public’s(awareness( of( its( benefits.( These( ac+ons( may(help( to( mi+gate( the( health( and( economic(burden(caused(by(influenza.((

Discussion(F(Recommenda+ons(

Further(work( in( alternate( study( samples( is( needed(to( validate( this( finding( and( to( determine( the(mechanisms( for( the( associa+on( between( kidney(stones(and(decreased(GFR.(However,(this(is(the(first(study( to( show( such( a( connec+on( in( a( na+onally(representa+ve( sample( of( the( United( States(popula+on.( Given( our( observa+ons,( the( serious(nature(of(renal(disease(and(the(increasing(incidence(of( nephrolithiasis( in( the( United( States,( further(inves+ga+on(is(warranted.(

Abstract(

Purpose:(to(highlight(key(points(from(major(sec+ons(of(the(ar+cle(

Emphasize(what(is(new(and(useful(

Component* Abstracted*from*

Major(purpose(of(study( (((Introduc+on(

Basic(procedures( (((Methods(

Main(findings( (((Results(

Principal(conclusions( (((Discussion(

Synopsis(–(Find(weaknesses(

Reliability of information about risk factors of chronic diseases collected in Missouri through the Behavioral Risk Factors Surveillance System. Synopsis (initial version) The Behavioral Risk Factors Surveillance System is widely used by health care authorities of the States to measure the prevalence of risk factors of chronic diseases. Despite its extensive utilization, only a few studies that assess reliability and validity of collected data have been conducted. A double testing study was carried out in the State of Missouri to assess reliability of information collected through the System. Authors repeatedly interviewed 222 people by phone, who passed full interview in March-April 1993. The repeated interview was conducted after 6-30 days following the first one. Repeatability of results was high for demographic data (kappa 0.85-1.00). Reliability of information about chronic diseases and risk factors thereof was also high. Kappa values ranged from 0.82 for the question about hypertension up to 1.00 for the question about smoking at that moment. In respect of the cancer survey procedures the reliability was lower for the knowledge of prostate cancer detection tests (kappa 0.21), than the tests used to diagnose cancer in women (mammography and smears). The question about attitude to smoking showed lower reliability than the question about actions to combat smoking. In general our data demonstrate flexibility of the System and its applicability to collecting information.

The Behavioral Risk Factors Surveillance System is widely used by health care authorities of the States to measure the prevalence of risk factors of chronic diseases. We carried out a double testing study to assess reliability of information collected through the System in the State of Missouri. We repeatedly interviewed 222 people by phone, who passed full interview in March-April 1993. The repeated interview was conducted after 6-30 days following the first one. Repeatability of results was high for demographic data (kappa 0.85-1.00). Reliability of information about chronic diseases and risk factors thereof was also high. Kappa values ranged from 0.82 for the question about hypertension up to 1.00 for the question about smoking at that moment. In respect of the cancer survey procedures the reliability was lower for the knowledge of prostate cancer detection tests (kappa 0.21), than the tests used to diagnose cancer in women (mammography and smears). The question about attitude to smoking showed lower reliability than the question about actions to combat smoking.

Synopsis(–(Published(version:(Find(weaknesses(

Introduction. Although tests to detect blood in feces are widely used to diagnose rectal cancer, there are no evidences that such use can result into decrease of mortality of this type of cancer. We conducted a randomized survey of the use of the method and showed its efficiency. Methods. 46,551 participants of the survey aged 50-80 were randomly selected either for the control group or for one of the test groups. The rectal cancer screening was carried out once a years in the first group, and once in two years in the second one. Those with positive test results passed through additional examination, including colonoscopy. Mortality statistics were collected for all participants over 13 years observation period. A group of experts determined causes of death, and an autopsist (pathologist) determined a stage of cancer for each case. Variations in mortality of rectal cancer were assessed by special statistical methods. Results. Total mortality of rectal cancer over the 13 year period was worth 5.88 per 1,000 (95% confidence interval 4.61-7.15) in the annually screened group, 8.44 (95% confidence interval 6.82-9.84) in the biannually screened group, and 8.83 (95% confidence interval 7.26-10.40) in the control group. This indicator in the first screened group (not the second one) was certainly lower as compared to the control group. This group showed detection of cancer at earlier stage, and the forecast of the survival rate in patients was better along with decrease of mortality. Conclusions. Annual tests to detect blood in feces decreased total mortality of rectal cancer by 33% within 13 years.

DECREASE OF MORTALITY OF RECTAL CANCER BY IMPLEMENTATION OF SCREENING FOR BLOOD IN FECES

Structured(Synopsis(

Finalizing(the(paper(and(submission(

•  Drag(a(+tle(•  Wri+ng(and(edi+ng(process(

•  Picking(a(journal(•  Last(sec+ons(:((

– References(– Special(men+on(

•  Transla+on(

Title(

What(goes(into(the(+tle?(

•  The(topic((T)(–(study(subjects(and(seing(o  Who,(what,(when,(where(

•  In(addi+on,(chose(one(or(two(among:(o  M(–(Methods(

o  R(–(Results(

o  C(–(Conclusions(

o  N(–(name(of(study(or(data(set(

Purpose:(to(provide(a(brief,(informa+ve(summary(that(will(asract(your(target(audience(

Highlight(what(is(new(and(useful(173(

Title(examples(

Title*•  Longitudinal(evalua6on(of(prostrateY

specific(an6gen(levels(in(men(with(and(

without(prostrate(disease(

o  An(injury(preven+on(program(in(an(AfricanFAmerican(community(

•  Smoking,(pregnancy,(and(source(of(preY

natal(care:(Results(from(the(Pregnancy(

Risk(Assessment(Monitoring(System(

o  Reduc+on(of(highFrisk(sexual(behavior(among(heterosexuals(undergoing(HIV(an+body(tes+ng:(A(randomized(clinical(trial(

******T*******M*******R*******C*******N*

•  +((((((((+((

o  +((

•  +(((((((((((((((((((((((((((((((((((+((

o  +((((((((+(((((((?(

Massive(mailing(does(not(effect(the(use(of(vaccines(among((MedicAir(Medical(insurance(recipients((Nurses(stress(factors(in(neonatal(Intensive(Case(Units:(American(Study((Experience(and(sa+sfac+on(of(primary(care,(secondary(Analysis(with(mul+level(modeling(((HIV(mortality(and(infec+vity(in(India:(assessment(of((na+onalFrepresenta+ve(census(1.1(mln(of(residents(

Title * ( ( ( ( ((((((((((((((((((T(((((M((((((R((((((C(((((((N((

(((((((((((((((((((((((((((((((((((((((((((((((((((((((((((

Examples(of(+tles:(Your(opinion?(

Racial(difference(of(Survival(with(Oral(cancer(in(Georgia((Time(of(experiment(implementa+on:(Racial(difference(of(Survival(with(Oral(cancer(in(Georgia:(1978F2001((Which(race(s)(under(higher(risk?((Reduced(survival(among(AfroFAmerican(pa+ents(with(oral(cancer(in(Georgia:(1978F2001((The(analysis(controlled(the(major(risk(factors:(Reduced(survival(among(AfroFAmerican(pa+ents(with(oral(cancer(in(Georgia(ager(Risk(Factors(Control:(1978F2001((Data(source?(Reduced(survival(among(AfroFAmerican(pa+ents(with(oral(cancer(in(Georgia(ager(Risk(Factor(Control:(Georgia(Registra+on(Index(SEER,(1978F2001((The(higher(risk(limited(by(several(subgroups(of(AfroFAmerican(pa+ents:(Reduced(survival(among(subgroups(of(AfroFAmerican(pa+ents(with(oral(cancer(in(Georgia(ager(Risk(Factor(Control:(Georgia(Registra+on(Index(SEER,(1978F2001(

Bri2sh*Medical*Journal*(BMJ):*The(+tle(must(include(study(design(if(presented(as(an(original(study(*American*Journal*of*Preven2ve*Medicine*Title(must(be(brief(but(informa+ve,(underline(but(not(describe,(serve(as(a(shortcut(but(not(an(offer,(reflect(what(was(done,(do(not(use(verbs,(include(nouns(for(easier(search,(do(not(use(symbols(or(abbrevia+ons(

*ICMJE*(Interna2onal*Commidee*of*Medical*Journals*Editors)*:*Short(+tles(easier(to(read.(Too(short(+tles(may(lack(the(informa+on(about,(for(example,(the(study(design.(Authors(encouraged(to(include(all(possible(informa+on(into(the(+tle(which(will(make(the(search(more(sensible(and(relevant.*

Title(requirements(

Wri+ng(the(ar+cle(and(submiing(it(to(a(journal(

Wri+ng(and(submiing(the(ar+cle(

•  Conduct(literature(review(•  Start(the(paper!(•  Conduct(study/analyze(data(•  Organize/summarize(results(succinctly(

•  Get(early,(frequent(feedback((in(pieces)(•  Formulate(your(key(message(

•  Apply(the(“new/useful”(test(•  Choose(your(target(audience(•  Choose(your(target(journal(•  Read(journal(instruc+ons(to(authors(

Wri+ng(and(submiing(the(ar+cle(

•  Drag((and(debug)(an(abstract(•  Write(the(first(drag(

•  Master(the(literature(

•  Relearn,(rethink,(and(rewrite(•  …and(rewrite,(rewrite,(rewrite(•  How(long?(•  Cri+cally(review(and(finalize(the(abstract(•  Asend(to(the(details(•  Submit(ar+cle(to(the(target(journal(

•  Have(a(“Plan(B”(180(

Conduct(literature(review(

•  Google(scholar(•  PubMed(–(try(“Single(Cita+on(Matcher”(•  Web(of(Knowledge(•  NIHFfunded(research((RePORTER)(•  Contact(leading(inves+gators(to(learn(about(inFpress(or(unpublished(work(

•  Scopus(•  Medline.ru(•  Elibrary.ru(

Start(the(paper!(

•  Yes,(even(before(you(do(the(study(•  Drag(the(introduc+on(–(perhaps(borrow(from(a(study(protocol(or(grant(proposal(that(you(already(wrote(

•  Drag(dummy(table(shells(and(figure(axes(for(Results(

•  Decide(which(sta+s+cal(methods(you(may(need(–(may(dictate(study(design(

Conduct(study/analyze(data(

Organize/summarize(results(succinctly(

•  Fill(in(dummy(tables(and(figures(with(real(data(

•  Drag(addi+onal(tables(and(figures(if(needed(–(look(at(published(ar+cles(for(poten+al(templates(

•  Summarize(each(table(or(figure(in(a(single(sentence(

Get(early,(frequent(feedback((in(pieces)(

•  Ask(coauthors/colleagues(if(your(tables/figures(and(text(summaries(are(clear/concise/compelling(

•  Give(presenta+ons(to(colleagues(and(at(conferences(

•  The(more(hurdles(you(clear(before(you(submit(your(paper(to(a(journal,(the(fewer(you(will(be(asked(to(clear(during(the(review(process(

•  Don’t(wait(for(a(complete(drag(to(begin(geing(feedback(

Formulate(your(key(message(

•  Keep(it(simple;(try(to(boil(down(to(a(single(sentence(

•  Your(message(must(contain(something(new(and(useful*

•  Make(sure(your(results(support(your(key(message(

•  The(message(may(change(as(you(develop(the(paper(

Apply(the(“new/useful”(test(

•  Journal(editors(are(interested(in(new(informa+on(that(is(useful(to(their(target(audience(

•  Does(your(study(meet(these(criteria?(

•  If(not,(the(effort(of(wri+ng(a(manuscript(may(not(be(warranted(

•  If(yes…(

Choose(your(target(audience(

What(audience(is(most(interested(in(your(message?(

o Clinicians?(

o Public(health(prac++oners?(

o Basic(scien+sts?(

o A(broad(audience?(

Choose(your(target(journal(

•  Journal(impact(factor(

•  Select(based(on:(o  Match(with(target(audience(

o  Strength(of(your(ar+cle(

•  Consider(aiming(high(–(reviewer(comments(from(a(highFlevel(journal(can(be(valuable(

•  However,(aiming(high(with(data(that(are(geing(“stale”(is(risky(

Read(journal(instruc+ons(to(authors(

•  Find(your(target(journal(“instruc+ons(for(authors”(on(the(Internet(or(in(an(issue(of(the(journal(

•  Is(your(key(message(relevant(to(the(target(journal’s(mission(statement?(

Drag((and(debug)(an(abstract(

•  Check(for(internal(consistency(o  Logical(flow(from(Purpose(to(Methods(to(Results(to(Conclusion?(

o  Conclusion(consistent(with(the(Purpose?(

•  If(you(see(flaws(in(the(Abstract,(ask(yourself:(o  Do(I(need(to(do(addi+onal(analyses?(

o  Addi+onal(literature(review?(

o  Addi+onal(thinking?(

Write(the(first(drag(

•  Write(for(your(target(audience((use(appropriate(terminology(or(jargon)(

•  Consider(using(an(outline(•  Don’t(spend(too(much(+me(on(the(grammar,(syntax,(or(details((only(you(need(to(understand(the(first(drag)(

Master(the(literature(

•  As(you(obtain(feedback,(colleagues(will(direct(you(to(new(references(

•  Update(your(PubMed(Single(Cita+on(Matcher(search((

•  Russian(Scien+fic(Cita+on(Index(•  (and/or(local(UZ(equivalent)(

Relearn,(rethink,(and(rewrite(

•  As(you(master(the(literature,(you(will(see(your(work(in(a(new(light(

•  Transmit(this(new(thinking(to(your(manuscript(

…(and(rewrite,(rewrite,(rewrite(

•  Most(papers(require(at(least(five(drags,(maybe(ten(–(save(and(date(them(all(

•  You(may(need(to(revise(your(key(message(

•  Perhaps(consider(changing(target(audience,(target(journal(

•  Perhaps(your(paper(is(now(beser(than(you(ever(imagined,(and(you(want(to(aim(for(a(higherFcircula+on/impact(journal(

How(long?(

•  How(long(should(your(manuscript(be?(

•  Follow(guidance(in(target(journal’s(instruc+ons(for(authors(

•  “Shorter(papers(get(luckier(faster”(

Cri+cally(review(and(finalize(the(abstract(

•  Check(again(for(internal(consistency((as(described(previously)(

•  Make(sure(the(abstract(is(fully*consistent(with(the(body(of(the(ar+cle(

Asend(to(the(details(

•  Carefully(review(and(comply(with(target(journal’s(instruc+ons(for(authors(

•  Call/eFmail(the(journal(if(you(s+ll(have(ques+ons(

Submit(ar+cle(to(target(journal(

Have(a(Plan(B(

Decide(on(your(next(target(journal(in(case(you(receive(a(rejec+on(

About(the(importance(of(opportunity(and(impact(

•  As(to(how(being(opportunis+c(can(lead(to(high(acceptability(of(research(grants(and(scien+fic(outputs((examples(of(bioterrorism(research(in(the(US(ager(2001,(or(the(large(number(of(papers(and(research(that(focus(on(Q(fever,(for(example,(ager(the(outbreak(in(the(Netherlands).(

•  But(watch(out(because(the(search(for(high(impact(publica+ons(can(lead(to(“miscarriages”((the(case(of(Wakefield)(

Wri+ng(for(Grant(Proposals(

Eugene(Elbert,(MS((Johns(Hopkins(University,(U.S.A.(

August(2012((

Phases(of(Grant(Wri+ng(

1.  Planning 2.  Preparing 3.  Writing 4.  Submitting

1.(Planning(

•  Research funder’s program areas and priorities. –  What other projects have been funded?

•  Read the instructions! •  For a specific RFP (request for proposals), READ

the RFP! •  Does your project match the funder’s needs? •  Do you have the capacity to do the proposed

project? •  Be familiar with the submission process

–  Is there an online submission process?

2.(Preparing(

•  Develop(your(idea(–  Is(it(new?(Interes+ng?((– What(are(the(specific(aims?(– What(is(your(research(design?(– What(will(the(outcomes(be?(

•  What(will(it(take(to(make(it(successful?(– Who(will(lead(the(project?((– Who(else(will(be(involved?((

•  Internal(staff(and(external(partners(– How(long(will(it(take(to(accomplish?(– How(much(money(will(it(take?(

2.(Preparing((con+nued)(

•  Get(organized(– Read(the(RFP(again(–  Is(a(leser(of(intent((LOI)(needed(before(the(full(proposal(can(be(submised?(

•  Develop(a(+meline(for(wri+ng(the(grant(proposal(– Be aware of deadlines. Start early!$

•  Assign(roles(in(the(proposal(process(– Will(different(people(write(different(parts?(

3.(Wri+ng(

•  Follow(direc+ons(– Are(you(including(everything(as(requested?(–  Pay(asen+on(to(format(and(page(limits.(

•  Make(it(easy(for(the(reviewer(to(read(–  Be(clear(and(concise(– Use(buzzwords(that(will(stand(out(and(show(your(work(is(aligned(with(the(funder’s(goals(and(mission.(

– Do(not(use(jargon(–  Spell(out(abbrevia+ons(and(acronyms(

3.(Wri+ng((con+nued)(

•  Title(– Make(it(interes+ng(and(clear(

– Does(it(capture(what(you(will(do?(– Look(at(+tles(of(other(projects(the(funder(has(funded(for(format(

•  Know(the(review(process(– How(will(the(proposal(be(scored?(–  Is(one(part(more(important(than(another?(

What(the(customer(wants…(

Innova+on((•  New(methods(for(old(problems((examples)(

•  Old(methods((elsewhere)(for(old(problems((examples)(

•  Any(method(for(new(problems((BE(THE(FIRST)(

o First(papers,(no(maser(how(precarious(become(seminal(ones((1)((

((1) Ugbomoiko et al. 2008. Parasites of importance for human health in Nigerian dogs: high prevalence and limited knowledge of pet owners. BMC Vet Research.

Parts(of(a(Grant(Proposal(

NOTE: These are are different for different funders – read the instructions! 1.  Cover(leser(2.  Summary(or(abstract(3.  Problem(or(Needs(statement(4.  Project(descrip+on(

•  Introduc+on(•  Objec+ves((•  Methods(

5.  Evalua+on(6.  Key(personnel(7.  Budget(

The(Sec+ons(

1.   Cover*leder*–  One(page(leser(addressed(to(the(funding(source(

and(signed(by(the(highest(official(

2.   Summary*or*abstract*3.   Problem*or*Needs*Statement*

–  State(the(problem(with(facts(and(evidence(that(support(the(need(for(your(project.(

–  Be(sure(to(use(accurate(data.(

The(Sec+ons((con+nued)(

4.  Project Description –  Introduc2on((

•  Provide(history(of(organiza+on(and(experience(of(your(team(

•  How(does(this(work(fit(into(what(has(been(done(previously(by(you(and(others?(

–  Objec2ves**•  List(2F4(Specific(Aims(of(the(project(•  Define(the(measurable(outcomes(of(your(program.(

–  Methods**•  What(ac+vi+es(that(will(take(place(to(achieve(the(objec+ves?(

•  What(is(the(research(design?(

The(Sec+ons((con+nued)(

5.*Evalua2on*–  How(you(will(measure(the(success(of(your(project?(–  Plan(for(con+nua+on(beyond(the(grant(period(

6.*Key*personnel*–  Describe(the(people(needed(to(do(project(– What(are(the(qualifica+ons(of(the(project(director(and(others?(

– What(are(their(roles(on(the(project(((Director,(Program(Manager,(Sta+s+cian,(etc.(

7.*Budget*–  How(much(will(it(cost(to(conduct(the(project?(–  Be(aware(of(funding(limitsF(do(not(ask(for(more(than(they(are(giving(out(

–  Provide(jus+fica+on(of(costs(*

4.(Submiing(

•  Review your work – Have you followed instructions? – Ask someone from outside of your team to

review your proposal to get a new perspective •  Revise

– Correct any errors – Make as clear and concise as possible

•  Submit – Follow directions

More(Informa+on(

Grant(Wri+ng(Tips(Sheet([hsp://grants1.nih.gov/grants/grant_+ps.htm]((Common(Grant(Applica+on((Na+onal(Network(of(Grantmakers)([hsp://www.nng.org/cga.html]((EPA(Purdue(University(GrantFWri+ng(Tutorial((Environmental(Protec+on(Agency)([hsp://www.purdue.edu/envirosog/grants/src/msieopen.htm]((Sample(proposals:([hsp://www.npguides.org/guide/sample_proposals.htm]((Grants(and(Grant(Proposal(Wri+ng((St.(Louis(University)([hsp://eweb.slu.edu/papers2/grant01v32e.pdf]((All(About(Grants(Tutorials((Na+onal(Ins+tutes(of(Health)([hsp://www.niaid.nih.gov/ncn/grants/default.htm]((

principles of scientific writing for an international audience

ontomolecularbiology

ontomicrobiology introduc

ng eugeneelbert

ng studyplan ar

c control

c papers

content makeposi

cengagementand coopera

Documents

foliar fertilization - scientific principles and field...

taylor principles of scientific management

cs206: principles of scientific university of california

principles of scientific computing

principles and practices of scientific originology-8391

diffusion cell apparatus: scientific principles and

audience resarch edited - nigeriacommunityradio.org · to...

outcome 2 scientific properties and principles of water unit...

the scientific principles behind submarines

principles and practices of scientific originology-8392

audience: therapeutic community and general public ......

scientific principles of strength training

taylor's “scientific management principles”:...

drug interactions: scientific and clinical principles

principles of scientific simulation

knr 205: scientific principles of coaching introduction

the principles of scientific management (1911)

the scientific study and application of psychological...

kin325-scientific principles of strength training-web.ppt

basic scientific principles of physiology